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ABSTRACT
The major histocompatibility complex (MHC) is the strongest genetic risk factor
for autoimmunity. It acts together with a corresponding TCR repertoire, yet, considering
the extent of the repertoire’s diversity, how this imposes disease susceptibility on a
population is not well understood. We address the hypothesis that shared or public TCR,
those present in most individuals, modulate autoimmune risk. High resolution analyses of
autoimmune encephalomyelitis-associated T-cell receptor chain (TCR showed
preferential utilization of public TCR sequences, implicating them in pathogenesis.
Disease-associated public TCR, when transgenically expressed in association with
endogenously rearranged T-cell receptor chain (TCR, could further endow unprimed
T cells with autoantigen reactivity. Enforced expression of two of six public but no
private TCR further provoked spontaneous, early-onset autoimmunity in mice. These
findings implicate public TCR in skewing repertoire response characteristics and
autoimmune susceptibility, demonstrate how single TCR chains can bias autoantigen
specificity, and suggest that subsets of public TCR sequences may serve as diseasespecific biomarkers or therapeutic targets.
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CHAPTER 1.

INTRODUCTION

T-cell Receptor
T Lymphocytes
A complete immune system involves different functional cell types, each of which
plays a particular role during immune response. Among these cells, the lymphocytes
occupy the central stage because they are the cells representing the specificity of immune
response. T cells constitute a major division of lymphocytes, which express TCR on the
cell surface. TCR is a heterodimer composed of two distinct chains, α and β or γ and δ.
The α and β heterodimers make up 95% of T-cells, while the γ and δ heterodimers make
up 5% of T-cells1. The αβ TCRs can be further divided into two sub-lineages based on
their distinct cell surface co-receptors, CD4 and CD8. Here we just focus on CD4+ T cells
bearing αβ TCRs. CD4+ T cells tend to differentiate into different functional cell subtypes
secreting their typical cytokines as a consequence of priming. For example, Type 1 helper
T cell (Th1) mainly produces interferon gamma (IFN- Type 1 helper T cell (h2)
produces interleukin 4 (IL-4), IL-5, IL-13, Th17 help cell produces IL-17 and regulatory
T cell (Treg) produces transforming growth factor beta (TGF- and IL-10.
T Cell Maturation
Pluripotent stem cells in bone marrow give rise to the T lineage precursors, and T
lineage precursors will travel from the blood to thymus for a serial of early maturation
events. In the thymic cortex, T lineage progenitors appear as CD4-CD8- double negative
form. During this stage, TCR chain will first undergo rearrangement. If the
rearrangement produces a productive TCR chain, it will pair with a surrogate  chain,
pre-T, otherwise will lead to clonal deletion. Functional TCRchain rearrangement will
be followed by a successful TCR chain rearrangement and expression of CD4 and CD8
co-receptors for the next double positive stage. Somatic recombination events for TCR
must be completed by the CD4+CD8+ stage and the CD4+CD8+double positive population
need to migrate to thymic medulla for further maturation. For positive selection, only the
CD4+CD8+ T cells with TCRs capable of low-affinity binding to a self-peptide-MHC
(pMHC) on thymic epithelial cells can receive a signal to survive, otherwise they will be
neglected and undergo apoptotic death2. Cells that undergo positive selection process will
begin to commit to either the CD4+ or CD8+ single positive lineage. Relatively, lowaffinity recognition of a self-pMHCI will lose CD4 and differentiate into CD8+ T cells,
while higher-affinity recognition of a self-pMHCII will lose CD8 and develop into CD4+
T cells3. During the commitment stage, differential expression of the lineage associated
transcription factors, as ThPOK or Runx3, will accompany the CD4+ helper lymphocyte
or CD8+ cytotoxic T lymphocyte (CTL) function4. On the other hand, since the somatic
recombination event is a totally random process, CD4+ or CD8+ T lymphocytes will by
chance produce high-affinity TCR recognizing auto-antigens in the thymus. These cells
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will undergo an elimination process and induce apoptotic cell death, which is referred as
negative selection. In alternative, some cells bearing high affinity TCR to self-pMHC will
induce the Foxp3 transcription expression, which causes the cells to differentiate into a
specific subpopulation, natural regulatory T cells (nTreg). The TCR affinity for selfpMHC of Treg is considered at the high end of the positive selection range but at the low
end of the negative selection range5, but Treg development is not well understood.
TCR Structure
The TCR is a disulfide-linked heterodimer. Each single chain is organized as
immunoglobulin (Ig) chains, consisting of a variable N terminal and a conserved C
terminal. Although TCR shares similar structural features as B-cell receptor (BCR), the
mechanism of antigen recognition is totally different. In contrast to recognizing intact
molecules, TCR recognizes a complex consisting of a peptide, which is derived by
proteolysis of the antigen and presented on a class I (MHC-I) or class II MHC (MHC-II)
molecule by an antigen-presenting cell (APC).
The adaptive immune system will encounter a large variety of pathogen-derived
antigens, which requires a corresponding TCR diversity. The TCR diversity is primarily
localized to three complementarity determining regions (CDRs) on each chain. Among
the six CDR loops, relatively conserved amino acids in the TCR CDR1 and CDR2
regions, encoded by the germ line V gene, are often used to bind exposed areas of the
MHC -helix. However, CDR3 loops, made up at least partially of non-germ line
encoded residues are hyper variety and are positioned to engage with MHC bound
peptide directly. The contact induced by CDR1 and CDR2 imposes the usual diagonal
mode of TCR binding on MHC. Meanwhile, this arrangement also allows flexibility in
the pitch formed by CDR1 and CDR2, allowing the TCR to accommodate CDR3 loops
and peptide ligands of different sequences and lengths and yet still bind the pMHC in
approximately the same orientation. Characterization of CDR3 sequence variation
therefore provides a good measure of TCR diversity in an antigen selected repertoire.
MHC
Historical Discoveries
The adaptive immune system consists of two components: antibody mediated
humoral immunity and T cell mediated cellular immunity. In contrast to antibodies
engaging with intact antigens, T cells function through interacting with the cell surface
bound small peptides via their heterodimer T cell receptors. The task of displaying cell
surface bound peptides for recognition by T cells is mediated by classical major
histocompatibility complex6.
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Studies about MHC associated immune response began from rejection of grafts
and tumor transplantation more than seventy years ago7-9. MHC represents a special case
as the immune responses are extraordinarily sensitive to the difference at the MHC.
Discovery of MHC suggests a co-evolutionary development of the lymphocyte receptors
which are somatically generated in the thymus, conferring them the ability to react well
with the foreign MHC but no longer react with the host MHC10.
MHC Structure
Until recently, great than 400 genes are mapped to the human or mouse Mhc. The
mouse Mhc is referred as H2 while in human it is referred as HLA (Human Leucocyte
Antigen). In most cases we specifically refer the “MHC” molecules to the class I MHC
and class II MHC based on their structural and functional properties. Both classes of
MHC are heterodimers with similar structures which composed of three domains, one helix/-sheet () superdomain that forms a peptide-binding site and two Ig-like
domains. A fully assembled class I MHC molecule is composed of a polymorphic 
chain noncovalently attached to the nonpolymorphic 2-microglobulin (m). The
peptide-binding cleft (12 domain) is formed by the heavy chain only, and the light
chain subunit, 2-microglobulin associated with 3 of the heavy chain to stabilize the
peptide binding. In contrast, a fully assembled class II MHC molecule is composed of a
polymorphic  chain noncovalently attached to a polymorphic  chain and the peptidebinding cleft is formed by two heavy chains (11). To present the peptide antigens on
MHC molecules, a seven stranded -sheet forms the floor of the binding groove and the
sides are formed by two long -helices. Polymorphic residues cluster within and around
the binding groove provide variation in structural and chemical properties, which
accounts for the specific peptide-binding motifs for each MHC molecules11-13.
Although both MHCs form a vice-like groove with two flanking -helices and a
-sheets formed floor, the peptide binding groove ends are quite open in class II MHCs,
which allows them to accommodate longer peptides. Generally, 8 to 10-mers peptides
were presented by class I MHCs, whereas 10 to 30 residues or longer peptides were
presented by class II MHCs. The anchor residues of the peptide are buried in specificity
pockets that differ from allele to allele14,15, leaving the upwarding amino acid side chains
bulging out of the groove for a direct interaction with the TCR. Termini sequences of the
long peptides may also extend out the binding grooves and contribute to the TCR
interaction.
MHC and T Lymphocytes
MHC molecules convey their function and trigger T cell responses via binding the
peptide antigens and presenting them for recognition by antigen-specific T lymphocytes.
Class II MHCs present peptides that originate from proteolysis of extracellular antigens
in endosomal-type compartments, whereas class I MHCs present peptides primarily
derived from intracellular degradation of proteins in the cytosol. Recognition of MHC
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molecules is T cell type restricted, as cytotoxic T cells preferentially engage with class I
MHCs, whereas T-helper cells preferentially engage with class II MHCs.
MHC and Autoimmune Diseases
Not only for transplant acceptance and immune responsiveness, the MHC is also
the principal genetic locus conveying risk for a number of human diseases. More than 40
diseases have been linked to the MHC, many of which are autoimmune disease in
nature16-19. Particular alleles of HLA class II loci, especially with DR and DQ are high
risk alleles for autoimmune diseases20. For example, studies identify the association of
the HLA-DRB1 locus in rheumatoid arthritis, as HLA-DR4 shared a common sequence
motif within the DR chain, suggesting preferential antigen presentation of self-epitopes
by these molecules21. In human type 1 diabetes, HLA genes are also thought to contribute
as much as 50% of the genetic risk for type 1 diabetes. The disease incidence is
significantly increased in patients with HLA-DR3-DQ2 and DR4-DQ8 haplotypes22,23.
Studies also indicated the homozygosity for HLA-DRB1*15:01 increases the probability
of developing multiple sclerosis ~7-fold24,25. In contrast, few non-MHC alleles impart
more than a 1.2-fold increase in risk26. The precise mechanisms underlying the
association of most of these diseases with the particular MHC haplotypes are not well
understood. Differential binding of self-antigen ligands may be one manner through
which MHC variants alter risk. However, even on a single cell, thousands of different
antigenic epitopes can bind to single MHC specificity. Therefore large numbers of tissuerestricted epitopes will associate with any MHC allele. As an alternative, MHC molecules
have been hypothesized to primarily confer risk by modulating the selection and
activation of pathologic effector and protective regulatory T cells27,28.
MHC Bias Pre-immune TCR Repertoire
Despite the lack of direct evidence, the hypothesis that TCRs are evolutionarily
selected to react with MHC is rational. The TCR specificity on developing thymocytes is
screened through positive and negative selection29,30.
One model that MHCs bias the pre-immune T cell repertoire was proposed, from
which a large number of CD4+CD8+ thymocytes failed positive selection and died by
neglect due to a lack of MHC specificity2. In addition, CD4, CD8, MHC-I and MHC-II
knockout mice were utilized to analyze for the pre-selection repertoire. Mice without
CD4 and CD8 still developed normal number of T cells, however, some of the cells could
be activated by foreign cells lacking MHC molecules. These results implicate that CD4
and CD8 molecule is required for interacting with MHC during pre-selection stage, in
effect forcing all selected T cells to have an affinity for MHC31.
Another model was proposed from the experiments performed on mice with
impaired negative selection. TCR and  chains expressed by the pMHCII-specific T
cells from those mice contact MHC primarily with the germ line encoded CDR1 and
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CDR2 regions, suggesting a co-evolutionary selection of TCR V domain and MHC
molecules. This finding implies that many pre-selection CD4+ CD8+ thymocytes are
deleted because of their intrinsic MHC specificity of TCRs and the only cells survive are
those with TCRs containing CDR3 that interfere with CDR1 and CDR2 mediated MHC
binding32.
Nevertheless, what we mentioned above doesn’t exclude the role of CDR3 in
mediating the pre-immune repertoire. CDR1 and CDR2 regions are located in the germ
line-encoded V domains whereas the CDR3 regions are generated by the random V(D)J
somatic recombination, which is responsible for interacting with peptide directly. Some
CDR3 were found to interfere with TCR-pMHC interaction and lead CD4+CD8+ T cell
die by neglect, in contrast, other CDR3 attenuated the CDR1 and CDR2 mediated MHC
binding and foster positive selection. Thus, the CDR1 and CDR2 domain of most TCR
and  chains can produce intrinsic MHC reactivity, CDR3 domain will sterically interfere
to varying degrees with this reactivity, producing a repertoire of TCRs with a wide
spectrum of affinities for self-MHC.
TCR Repertoire
TCR Repertoire Diversity
Similar to the rearrangement of Ig heavy and light chains, the diversity of TCR
repertoire is generated from somatic recombination. The V(D)J somatic recombination
introduces two types of diversity: combinatorial diversity and junctional diversity. A
functional TCRαβ heterodimer is generated through randomly arrange different gene
segments, which refers to variable (V), diversity (D) and joining (J) gene segments to a
constant region (C) in the case of TCRβ chains, or V-J-C in TCRα chains. In the human
TCR loci, there are 42 TRBV, 2 TRBD, 12 TRBJ, 43 TRAV and 58 TRAJ functional
gene segments, whereas in mouse TCR loci, there are 35 TRBV, 2 TRBD, 12 TRBJ, 71
TRAV and 51 TRAJ functional gene segments33. The lymphocyte specific V(D)J
recombinase will recognize the conserved recombination signal sequences located
adjacent to V,D,J exons, delete intervening DNA and ligate the segments. Therefore, the
amount of combinatorial diversity is decided by the possible number of combinations of
the germline V, J, D gene segment numbers. In addition, the combinatorial diversity is
further enhanced by the juxtaposition of two different, randomly generated TCR and
TCRchain. On the other hand, the largest contribution to the diversity is coming from
junctional diversity, which involves removal or addition of nucleotides between VD, DJ,
or VJ junctions. Removal of nucleotides by nucleases may lead to the generation of novel
amino acid sequences or to out-of-frame nonfunctional products, while DNA polymerase
mediated asymmetric breaks repair or TdT mediated nucleotide addition will generate
non-germ line coded sequences34.
Theoretically, these events will produce a potential repertoire diversity of up to
1015 different TCRs in mice1 and 1018 in humans35. Given that only ~3% of T cells will
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survive after thymic selection, this leaves more than 1013 possible TCR diversity for mice
and 1016 for humans in the periphery if the full repertoire could form36. However, the
estimated numbers of T cell clonotypes are only about 106 in mice37 and 107 in humans1
in the peripheral circulation, several orders of magnitude less than the theoretical
maximal diversity.
Public TCR Repertoire
Unlike antibodies, which can engage antigens in highly variable manners, TCR
heterodimers associate with pMHC in largely stereotypical orientations that require
significant energy contributions from both the TCR and  chains6. Considering this,
public TCR or  chains would not be expected to bias TCR recognition, as each public
TCR or  chain may associate with a vast array of distinct  or  chains that contribute
roughly equally to recognition. However, it has also been shown that certain TRAV and
TRBV chains are preferentially employed in specific responses38-41. In some extreme
cases, certain TCR sequences are broadly shared between individuals, and therefore can
be referred to as a ‘public’ repertoire42-44.
What is the underlying mechanism of TCR bias? Biased TCR repertoire may
result from different factors. First, a number of analyses were performed on public CD8+
T cell responses to persistent infections such as human HIV45,46, Epstein-Barr virus
(EBV)47,48 and cytomegalovirus (CMV)49-51, suggesting chronic antigenic stimulation
can impose the selective expansion of T cell clonotypes with optimal TCR structural
features49,51 in immune responses. Nevertheless, chronic viral antigenic stimulation in not
necessarily required for promoting biased TCR usage, since it is also found in acute viral
infection52-55 or after immunization39,56-59. The other evidence of biased TCR usage was
also be found associated with autoimmune disease such as multiple sclerosis56,60,61 and
type 1 diabetes62 or alloreactivity63.
The other events influencing the TCR bias may happen either in the pre-selected
repertoire or during thymic selection. A model of convergent recombination was
proposed by Venturi et al., as a process whereby multiple recombination events
‘converge’ to produce the same nucleotide sequence and multiple nucleotide sequences
‘converge’ to encode the same amino-acid sequence. This process enables some TCR
sequences to be produced more frequently than others during somatic recombination44.
On the other hand, studies indicated that CDR1 and CDR2 domains of TCR V regions are
‘hard-wired’ with an inherent propensity to recognize conserved features in the MHC helices, thymic selection may shape the TCR repertoire with intrinsic TCR reactivity to
self-MHC. The consequence of this bias towards MHC can result in a preferential usage
of certain V regions in the TCR repertoire64,65.
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Treg Cells
Treg Identification
As we mentioned above, both positive and negative selection shape the preimmune TCR repertoire based on TCR affinities66. Besides that, a specialized lineage of
CD4+ T cells with TCR affinities for self-MHC will differentiate into regulatory T cells.
Tregs play an essential role in mediate peripheral tolerance67,68. Tregs derived from
thymus are referred to as natural Treg cells (nTreg), whereas Tregs generated in
secondary lymphoid organs by foreign antigen stimulation are referred as induced Tregs
(iTreg)69.
It was proposed more than 40 years that a distinct subset of T cells generated from
thymus is responsible for immune suppression70. The first evidence came from mouse
neonatal thymectomy studies, mice thymectomized on the third day after birth (d3Tx) of
neonatal mice developed organ specific autoimmune disease. However, the autoimmune
disease could be totally prevented by thymus transplantation between days10 and 15 of
life. This observation suggests thymocytes may contain a subset of suppressor cells
which are exported from the thymus later than autoreactive T-cells71. Furthermore,
Sakaguchi and his colleagues identified and characterized this subset of suppressor CD4+
T-cells their constitutively expressed CD4 and IL-2 receptor  chain (CD25)72,73.
However, CD25 is highly expressed on both activated CD4 and CD8 T cells,
compromising its usefulness as a Treg restricted marker74. A major advance in the study
of Treg was derived from the discovery of a genetic mutation in humans,
immnunodysregulation, polyendocrinopathy and enterophathy, X linked syndrome
(IPEX). The mutation genetic locus encodes a forkhead winged-helix transcription factor
family member Foxp375. Similar as studies on scurfy mice, Foxp3-gene knockouts
resulted in complete loss of Treg cells and severe autoimmune disease76. The most
important thing is that expression of Foxp3 is specifically restricted to Treg lineage and
required for Treg cell development in the thymus74,77-80. Foxp3-GFP knocked in mice
were developed by Rudensky et al., permitting ready identification and isolation of
Foxp3+ Treg by cell sorting81. Treg cells make up approximately 10%-15% of mouse
CD4+ lymphocytes, and approximately 5%-10% of CD4+CD8- thymocytes74.
Treg Development Models
The common view about Treg origin is that the majority of Tregs are generated in
the thymus as a distinct T cell subpopulation, bearing with high-affinity TCR-peptideMHC interactions. Studies were conducted using several double transgenic mice models.
When TCR transgenic mice bearing a TCR specific for a determinant (S1) derived from
influenza hemagglutinin (HA) were crossed to mice expressing the HA transgene, the
transgenic T cells developed a large portion of Tregs rather than deletion. In contrast,
thymocytes bearing TCRs with low affinity to S1 reduced the percentage of Treg, which
suggested that the selection of Treg appeared to require a TCR with high affinity for self-
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pMHC82-84. But why only 50% of the exported thymocytes developed into Tregs rather
than 100% in that mice model is not clear, implying there is a “niche” size for Treg cell
development85. An alternative model for the differentiation for thymic Treg was proposed
by van Santen et al.86. In experiments where the transgenic TCR was confronted with
their specific pMHC ligand in the thymus, the percentage of Treg cells increased without
a change in absolute numbers. Thus, selective survival might be an alternative
explanation for Treg differentiation.
Mature nTregs are emigrants from the thymus, however, it is not the only place
for the generation of Foxp3+ Treg cells. In some extrathymic condition, Foxp3+ T cells
can be induced from peripheral non-Treg cells, referred as adaptive Tregs or induced
Tregs (iTregs), which acquire similar suppressor phenotype and function as nTreg87. In
vivo, cell transfer experiment demonstrated that approximately 5% splenic CD4+CD25- T
cells were converted to CD4+CD25+ suppressor cells in RAG -knockout recipient mice
which expressed transgenic antigens88. TGF- is a pivotal factor for Treg generation in
vitro through triggering the Smad2/3 signal pathway89. In addition, the vitamin A
metabolite retinoic acid (RA), which is produced by a subset of DCs in the gut-associated
lymphoid tissue, is able to inhibit IL-6 mediated Th17 cell induction. In the presence of
TGF-, RA facilitates the convention of Foxp3- T cells to Foxp3+ Treg cells90,91.
Furthermore, low doses stimulation in sub-immunogenic conditions can induce Treg
generation in the periphery particularly to self-components that do not lead to tolerance in
the thymus87,92. That may explain why majority iTreg is generated in the gut-associated
lymphoid tissue since it is enriched for commensal bacteria antigens, and CD103+ DCs,
which serve as the main source for RA and TGF-93,94.
Treg Repertoire
How can Treg precursors commit to Treg lineage instead of negative selection if
they possess high-affinity TCR-peptide-MHC interactions? By using GFP-Foxp3 knockin mice, Hsieh et al. was able to reveal the selection of T cells into the Treg lineage at the
transition from DP to SP, indicating commitment of Treg lineage and negative selection
at the same stage95. In addition, double transgenic mice model revealed that the
proportion of regulatory T cells declined with decreased TCR affinity and the affinity
range permissive for Treg development overlaps considerably with the range promoting
negative selection96. However, Treg cell development is accompanied by deletion of T
cells sharing the same TCR, and the relative proportions of cells undergoing either
negative selection or commitment to Tregs change with the doses of agonist
peptide/MHC96. These results suggest that Treg commitment may be due to other
intrinsic and extrinsic factors besides TCR affinity.
What factors decide the commitment to Treg lineage instead of non-Treg lineage?
TCR repertoire analysis has been applied on Foxp3 deficient mice. The same TCR as
used by suppressive Treg cells in normal mice could be used by pathogenic autoimmune
T conventional cells (Tconv), suggesting normal mice might have a population of selfreactive Tconv that express the Treg self-reactive TCR repertoire95. Very few studies
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have addressed in detail either the TCR repertoire of Treg or their antigen specificity due
to the limitation of methods. TCR repertoire analysis has been shown great potential to
compare the TCR repertoire between Treg and Tconv. TCR repertoire analysis in pre
immune mice demonstrated that naturally arising Tconv and Treg cells share a portion of
TCRs that, depending on the experimental model and evaluation method, varies from
10%–42%97-99. Not only to investigate the TCR repertoire in thymus, has TCR
repertoire analysis also been utilized to survey the interconvertion between Treg and
Tconv repertoire at the loci of inflammation. In one diabetes model, only limited Treg
and Tconv cell overlap was found in islets, suggesting that these cell types were not
interconverting at the site of inflammation100. Meanwhile, Liu et al. performed repertoire
analyses and functional assessments of isolated TCRs from TCR retrogenic mice
immunized with MOG-EAE. The result demonstrated that that ontogenically distinct
Treg and Tconv cell repertoires with convergent specificities for autoantigen respond
during autoimmunity101. In addition, high-throughput sequencing and global analysis
were further conducted on normal MOG-EAE mice, showing differences in sequence and
physical characteristics distinguish Treg and Tconv TCR102.
Experimental Autoimmune Encephalomyelitis (EAE)
As the most predominant autoimmune disorder of the central nervous system
(CNS), multiple sclerosis (MS) affects approximate 2.5 million people worldwide103.
Over the last eighty years, scientists developed EAE models to elucidate the pathogenesis
of the disease or to test new therapeutic approaches104. EAE is a demyelinating disease of
the CNS, with T cell and macrophages dominating the inflammatory response, causing
destruction of axonal myelin sheath in the CNS and further neuronal damage105. Disease
is most commonly induced in susceptible mice strains by immunization with
immunodominant epitopes of myelin proteins such as MBP1-9 (myelin basic protein)106,
PLP139-151 (proteolipid protein)107, or MOG35-55 (myelin oligodendrocyte glycoprotein)108
together with complete Freund’s adjuvant and pertussis toxin. Activated encephalitogenic
T cells then infiltrate into the CNS and initiate disease. Mice usually develop an acute
episode of paralysis following by a spontaneous resolution. The disease symptoms of
EAE reflect the anatomical location of the inflammatory lesions, which is similar to MS.
However, the pathology of MS is quite heterogeneous since abnormal CD4+ T-cells,
CD8+ T-cells, B-cells and activated microglia/macrophages are correlated for the lesion
development in MS patients105. Though there is no single EAE model, which can mimic
MS as a whole, this will not preclude the study about the self-limiting nature of this CNS
disease model. Foxp3+ regulatory T cells (Treg) are the effective suppressors responsible
for disease resolution a regulatory network capable of suppressing vigorous auto-reactive
response109-111. This model therefore provides a good basis to investigate regulatory
mechanisms in CNS autoimmune disease.
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High-throughput Sequencing (HTS)
The adaptive immune system generates a large pool of T cell clonotypes to fight
against innumerous pathogenic antigens. The germ line genome is limited in size,
however, the immune system compensates this by introducing the V(D)J somatic
recombination. Focused on TCR, the receptor diversity is focused on a small segment of
the TCR and  chain genes, the CDR3 region, which directly engage with peptide-MHC
complex6. On average, it is grossly estimated that there are 20 - 200 T cells for each
single clonotype in the periphery112, however, the frequencies vary dramatically due to a
cell’s specificity and immunologic history113. Analyses of the TCR repertoire may
provide insight into the nature and dynamics of these immune responses114-116.
Traditional sequencing method may no longer meet the needs to investigate TCR
repertoire systematically due to low time cost efficiency and limited sample size97,101.
Advances in high-throughput sequencing have enabled the development of a powerful
new technology for probing the adaptive immune system115,117. First of all, high-through
put immunosequencing allows millions T cell receptor sequences can be read in parallel
from a single sample. The dynamics of an adaptive immune response, which is based on
clonal expansion and contraction, can be monitored in real time at high sensitivity and the
global properties of the adaptive immune repertoires can be studied. Second, the highly
variable CDR3 regions, which serve as tag for TCR are pretty short (~15-60 nt), making
them amenable to rapid interrogation. Third, HTS has been successfully employed in
many global adaptive immune repertoire property analyses where there is immune
compromise, suggesting a potential clinical utility. Those areas cover the aging immune
system118, immunotherapy119 and autoimmune disease120, etc. On the other hand, public
clonotypes are associated with human disease or common pathogens within a specific
HLA context121. Identification of public clonotypes in patients provides a potential
diagnostic application.
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CHAPTER 2.

METHODOLOGY

Mice and Materials
Mice
C57BL/6J (B6), B6.129P2-Tcrbtm1Mom/J (TCRβ-/-), B6.SJL-Ptprca Pep3b/BoyJ
(CD45.1) and B6.129P2-Rag1tm1Mon/J (Rag1-/-) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). GFP-Foxp3 mice on a B6 background were obtained from
Dr. A. Rudensky (NYU)74. Mice were bred under specific-pathogen-free conditions, and
animal experiments were carried out in compliance with Institutional Animal Care and
Use Committee guidelines.
Monoclonal Antibodies
Red blood cells were lysed prior to staining. Fc receptors were blocked with mice
CD16/CD32 antibody specific for Fcγ R III/I (Miltenyi Biotec, San Diego, CA). Cell
surface staining was performed for 20 min at 4°C in PBS containing 0.1% sodium azide
and 2% (vol/vol) fetal bovine serum (FBS). Monoclonal antibodies (Ab) specific for CD4
(clone RM4-5), CD8 (clone 53-6.7), TCRβ (clone H57-597), CD44 (clone 1M7),
CD45RB (clone C363.16A), CD69 (clone H1-2F3), CD45.1 (clone A20) or CD45.2
(clone 104) were from BD Biosciences (San Jose, CA). For intracellular staining, cells
were first stained with surface markers, fixed, permeabilized and stained for intracellular
Foxp3 (clone FJK-16s) with the Foxp3 Staining Buffer Set (eBioscience, San Diego, CA).
For cytokine staining, cells were first treated with 1x Cell Stimulation Cocktail
(eBioscience) at 37°C for 4 hr, stained for surface markers in the presence of 10 μg mL-1
Monensin (eBioscience), followed by fixation and permeabilization and staining for IL17A (clone eBio17B7, eBioscience) and IFN-γ (clone XMG1.2, BD Biosciences). Flow
cytometric analysis was performed on an LSRFortessa (BD Biosciences) and analyzed by
using FlowJo software (Tree Star, Ashland, OR).
High-throughput Sequencing
EAE Immunization
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) was synthesized by St.
Jude Hartwell Center for Biotechnology and HPLC purified prior to use. EAE was
induced and scored as described102. In brief, B6 mice were s.c. immunized with 100 μg
of MOG35–55 peptide in complete Freund's adjuvant containing 0.4 mg Mycobacterium
tuberculosis H37RA (Difco, Lawrence, KS). Two hundred nanograms of pertussis toxin
(List Biological Laboratories, Campbell, CA) was administered i.v. on day 0 and day 2.
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Clinical scoring was: 1, limp tail; 2, hind limb paresis or partial paralysis; 3, total hind
limb paralysis; 4, hind limb paralysis and body or front limb paresis or paralysis; 5,
moribund.
Cell Isolation
Mice were sacrificed by CO2 asphyxiation and the spleens, lymph nodes, thymi
were removed and collected individually in 6cm diameter dishes. Cells from these tissues
were squeezed through the 70μm nylon mesh by gently mashing with the rubber end of a
plunger from a 3cc syringe. A single cell suspension was created and harvest into a 50ml
conical tube. Usually red blood cells need to be lysed for splenic cells.
For CNS tissue, the mice were anesthetized by intraperitoneal administration of a
lethal dose of Avertin (0.5ml of 2.5%, Sigma-Aldrich, St. Louis, MO). After complete
anesthetization, the mice were placed on a polystyrene board and pinned down. The mice
abdomen and chest were opened. The right atrium of the heart was cut open, and a 271/2
g needle was immediately inserted into the left ventricle slowly perfused with PBS. After
PBS perfusion, the brain and spinal cord were gently collected. The CNS tissue was
gently mashed through a 70μm nylon cell strainer with the rubber end of a plunger. The
cell suspension was spun down at 1500 rpm for 10 minutes and resuspended in 15ml of
37.5% Percoll (GE Healthcare Bio-Sciences, Piscataway, NJ). After centrifuging at 1500
rpm for 10 minutes with soft break, supernatant was gently discarded. The cell pellets
were washed with PBS and then spun down again.
Cell Counting
Cell numbers were automatically calculated by Beckman cell coulter. As an
alternative, adequately diluted cell suspension was thoroughly mixed with trypan blue
and read on hemocytometer chamber. The total number of live cells was counted in the
four corner squares. The cell concentration per ml was calculated as following equation.
Cells per ml = the average count per square x the dilution factor x 104
Cell Sorting
T cells were isolated from spleen, CNS, and thymus as described. Splenic and
CNS cells were stained with CD4 Ab and flow cytometrically sorted into CD4+ GFPFoxp3+ (Treg) and CD4+ GFP-Foxp3- (Tconv) populations. Some splenic Tconv cells
were further sorted into CD4+CD44hiCD45RBlo (memory/effector) and
CD4+CD44loCD45RBhi (naïve) populations. Thymic T cells were stained with CD4,
CD8, and TCR Abs and sorted into CD4+CD8+TCRlo double positive, CD4+CD8-Foxp3-,
and CD4+CD8-Foxp3+ single positive T cell populations. Flow cytometric sorting used a
Reflection (Sony Biotechnology, Champaign, IL) sorter.

12

RNA Isolation and cDNA Transcription
Sorted cell populations were lysed, and total RNA was isolated using the RNeasy
Kit (Qiagen, Valencia, CA). cDNA was produced using the Omniscript RT Kit (Qiagen)
according to the manufacturer’s instructions. cDNA was amplified with C (5’GGGTGGAGTCACATTTCTCAGATC-3’) and Vb8.2 (5’CCCCCTCTCAGACATCAGTGTAC-3’) specific primers using the High Fidelity PCR
System (Roche, Indianapolis, IN). The ~200-bp PCR product was purified by agarose gel
electrophoresis and column purification (QIAquick Gel Extraction Kit, Qiagen).
DNA Preparation and Sequencing
DNA end repair was performed according to our previous protocol102. First,
incubate the PCR products from cDNA transcription with 15U T4 DNA polymerase
(NEB, Beverly, MA), 50U T4 polynucleotide kinase (NEB), 0.4 mM 2’-deoxynucleoside
5’-triphosphate, 1x T4 ligase buffer with 10 mM 2’-deoxyadenosine triphosphate
(Promega, Madison, WI), and 5U Klenow enzyme (Promega) for 30 min at 20°C. The
product was subsequently purified by using the QIAquick PCR Purification Kit (Qiagen).
To add adenosine tags on the DNA 3’ ends, purified DNA was incubated with 25U
Klenow fragment (NEB), 1x Klenow buffer, and 0.2 mM 2’-deoxyadenosine triphosphate
for 30 min at 37°C. The product was purified by using the MinElute Reaction Cleanup
Kit (Qiagen) and concentrated to 10 ul volume. Next, sequencing adapters were ligated
onto the DNA products, adding 3 mM Index PE adapter Oligo Mix, 5 ul Quick DNA
ligase (NEB), and 1x ligase buffer, and incubated for 15 min at 20°C. To remove
unligated adapters, the product was purified using the QIAquick Gel Extraction Kit
(Qiagen). Samples were each divided into 3, and InPE 1.0 and 2.0 (Illumina®, San
Diego, CA) and Index primers were next linked to the DNA, using the Phusion DNA
Polymerase Kit (Finnzymes Oy, Eskoo, Finland) with the following PCR condition: 19
cycles at 98°C 10 sec, 65°C 30 sec, 72°C 30 sec. The PCR products were purified using
the QIAquick PCR purification kit, as above. Each sample was divided into 3, and
equimolar quantities of each sequenced over three lanes of a flow cell with an Illumina®
Genome Analyzer IIx sequencer using a 125 bp (plus 6 bp barcode) recipe to obtain
single-end reads that cover the entire CDR3 region.
Raw Data Trim
Raw data was demultiplexed and filtered using CASAVA 1.6.0. The data was
subsequently trimmed for the presence of adapter sequences using CLC Genomics
WorkBench v4.0. The Illumina® 125-bp reads were then scanned for V and J
sequence homology immediately external to the C and F residues bordering the CDR3
using cross_match http://www.phrap.org/. To identify CDR3 sequences, reads were
filtered based on the cross_match results using the following criteria: (i) 100% sequence
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identity for both V and J mapping; (ii) translated amino acid sequence between V and
J is in the correct frame and reveals a translated product (no stop codon); (iii) the
deduced CDR3 amino acid sequences between the V and J sequences begin with the
conserved C and end with a FGXG, FAXG or HGXG motif. The deduced CDR3 nt
sequences were then scanned using the Phred quality score cutoffs of 0, 10, 20 or 30, and
reads with CDR3 nt sequence containing at least one low quality base at a given cutoff
level were filtered out
Retrogenic Mice Models
Molecular Subcloning
The backbone construct is MSCV-IRES-GFP122, which was further designed for
the sake of our experiments101,123. To generate the TCRβ1-GFP construct which expresses
single TCR chain, the TRBV13-2+ TCR segment was PCR amplified from
1MOG244.2123 (forward primer: 5’GCCGAATTCGCCACCATGTCTAACACTGCCTTC-3’; reverse primer: 5’GGGTAGCCAACTCGAGAATGAG-3’) and subcloned into EcoRI/XhoI sites in the
IRES-GFP retroviral vector. The TCRβ1-CDR3-J segment was created by annealing a
pair of complementary oligos synthesized by St. Jude Hartwell Center (sense oligo: 5’TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCTGTGCCAGCGGTGAG
ACTGGGGGAAACTATGCTGAGCAGTTCTTCGGACCAGGGACACGACTCACCG
TCCTAGAA-3’; anti-sense oligo: 5’GATCTTCTAGGACGGTGAGTCGTGTCCCTGGTCCGAAGAACTGCTCAGCATA
GTTTCCCCCAGTCTCACCGCTGGCACAGAAGTACACTGATGTCTGAGAGGGG
GTAGCCAAC-3’). This was subcloned into the XhoI/BglII cloning sites of 1MOG244.2
vector to synthetically recreate TCR1. Other TCRβ constructs were similarly
constructed synthetically and the oligo sequences were in Table A-1. pMOTII plasmid
(gift from Dr. D.Vignali; SJCRH) contained the entire OTII TCR (Vα2-2A-Vβ5.1)
cassette. OTII TCRβ sequence was PCR amplified (forward primer: 5’GCCGAATTCGCCACCATGTCTAACACTGCCTTC-3’; reverse primer:
GTCACATTTCTCAGATCTTCTAG-3’), digested with EcoRI/BglII, and then
subcloned into the EcoRI/BglII sites of TCRβ1-GFP (Figure B-1a).
To reconstitute a polycistronic MSCV construct expressing the unique TCRof
1MOG244.2 and theTCRchain, 1MOG244.2 and TCRβ1-GFP constructs were both
digested with EcoRI/XhoI. The digested fragment from 1MOG244.2, which included an
entire TCRchain, a T. asigna 2A sequence and the TRBJ 13-2 segment, was ligated
with the cut TCRβ1-GFP vector, generating a new plasmid named as 244.2-TCRβ1GFP (Figure B-1b). The other polycistronic constructs expressing different TCRchain
but fixed TCRchain were reconstituted on 244.2-TCRβ1-GFP. The secondary
BglII behind the CDR3was destroyed without disturbing the amino acid sequences by
using Quick change site directed mutagenesis kit (Agilent Technologies, Santa Clara,
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CA). Different TCRchains including TRAV and CDR3 were amplified and subcloned
into the EcoRI/BglII cloning sites of 244.2-TCRβ1-GFP.
Retroviral Transduction
Retrovirus was produced as described123. Ten micrograms of retroviral construct
and packing plasmid were cotransfected into 293 T cells using the calcium phosphate
transfection method, and the cells were incubated in DMEM supplemented with 10%
fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 100 U mL-1 penicillin, 100
µg mL-1 streptomycin, and 292 µg mL-1 L-glutamine (Invitrogen Life Technologies) at
37°C for 36 hr. Supernatant was collected twice a day for 72 hr and used to infect
GP+E86 retroviral producer cells in the presence of 8 μg ml-1 polybrene (Sigma-Aldrich,
St. Louis, MO).
Generation of Retrogenic Mice
Donor TCRβ–/– mice received 0.15 mg 5-fluorouracil g−1 body weight i.p. (APP
Pharmaceuticals, Schaumburg, IL). After 48 hr, bone marrow cells were harvested from
the femurs of the mice and cultured in complete Click's medium (Invitrogen, Grand
Island, NY) supplemented with 20% fetal bovine serum (FBS), 20 ng ml−1 mIL-3, 50 ng
ml−1 hIL-6, and 50 ng ml−1 mSCF (Pepro Tech, Rocky Hill, NJ) for 48 hr. Next, the
hematopoietic progenitor cells (HPCs) were collected and cocultured for another 48 hr
with irradiated (1200 rads) GP+E86 retrovirus producer cells in complete Click's medium
supplemented as above and with 6 μg ml-1polybrene. Then, the HPCs were harvested, resuspended in PBS supplemented with heparin (10 U per recipient mouse, SigmaAldrich), and injected i.v. into the sublethally irradiated (450 rad) Rag1-/- recipients at a
ratio of two recipient mice per bone marrow donor. Transduction efficiency was
confirmed by flow cytometry for GFP expression. Engraftment was analyzed on day 28
after HPC transplantation.
Clinical Evaluation
Cohorts of retrogenic mice were generated and clinically monitored for ≥120 days
after HPC transfer. Mice were processed and submitted for histopathologic examination
either during the peak disease or after 120 days if healthy. Full necropsy including CNS
tissues was processed on at least three mice for each cohort for concurrent inflammatory
and degenerative lesions. Paraffin-embedded tissue samples were stained with
hematoxylin and eosin (H&E) and, where appropriate, CD3. The severity of spontaneous
EAE was scored by using the predetermined qualitative and semiquantitative criteria: 0,
lesions absent, 1, minimal to mild inconspicuous lesions, 2, conspicuous lesions, 3,
prominent multifocal lesions, 4, marked coalescing lesions.
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Chimeric Mice
HPCs from CD45.1-CD45.2+ TCRβ-/- mice were transfected with TCRβ1
retrovirus as described above. Retrogenic HPCs were harvested and diluted with
CD45.1+CD45.2- syngeneic B6 bone marrow cells, and subsequently injected into
irradiated (450Rads) CD45.1+CD45.2- Rag1-/- mice at a ratio of two recipient mice per
bone marrow donor. Engraftment was analyzed at day 28 after HPC transplantation.
Disease incidence was monitored for at least 60 days.
Cell Proliferation Assay
Splenic cells were isolated from retrogenic mice and CD4+ T cells were purified
with anti-CD4 Ab (L3T4) coated microbeads (Miltenyi Biotec, San Diego, CA) and
enriched using MACS separation columns (Miltenyi Biotec). Purified CD4+ T cells were
co-cultured at 5 × 104 per well in 96-well plates with 2 × 105 irradiated (3500 rad)
syngeneic splenic APCs and stimulated with 100 μg ml-1 MOG35-55 peptide for 72 hr,
pulsed with 1 μCi 3H-thymidine (PerkinElmer, Boston, MA), and harvested 16 hr later
for scintillation counting. To further assess the dividing cell fraction, the Cell Trace violet
cell proliferation kit (Invitrogen) was used according to the manufacturer’s instruction.
Cells were labeled with 5 μM CellTraceTM violet prior to culture with the indicated
stimuli for 72 hr. The cells were then stained with surface markers and 7-AAD (BD
Biosciences) and viable CD4 T cell proliferation was measured by dye dilution. As a
positive control, 1 μL Mouse T-Activator CD3/CD28 Dynabeads (Invitrogen) were added
to positive control wells to at a 1:1 bead-to-cell ratio.
Cytokine Analysis
Culture supernatants were collected at 48 hr and analyzed for IL-2, IL-4, IL-10,
IFN-g, and IL-17A using the Milliplex MAP mouse cytokine/chemokine immunoassay
kit (Millipore, Billerica, MA) on a Luminex (Bio-Rad) instrument. For intracellular
cytokine staining, cells were cultured with 1x Cell Stimulation Cocktail (eBioscience) at
37°C for 4 hr, stained for surface markers in the presence of 10 μg ml-1 monensin
(eBioscience), followed by fixation and permeabilization, and intracellular staining with
IL-17A and IFN- Abs.
Retroviral Transfection of CD4+4G4 Hybridoma Cell
Transfected GP+E86 retroviral producer cell lines were expanded in 75ml flasks.
Twelve milliliter of retroviral supernatant was harvested from each day confluent
GP+E86 producer cells. To transfect hybridoma cells, 1x106 TCR-deficient CD4+ 4G4
hybridoma cells101 were resuspended in 3 ml retroviral supernatant in the presence of 6μ
g/ml polybrene. The cell suspension was centrifuged at 1800 rpm, 8°C for 90 minutes.
The infected cells were then cultured at 37°C for 48hrs and cytometrically sorted twice
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for the GFPhighTCRhigh population and expanded. The purity of the GFPhighTCRhigh 4G4
cells was confirmed by flow cytometry (BD FACSCalibur).
Enzyme-linked Immunosorbent Assay (ELISA)
In 96 well flat bottom plates, 1x105 hybridoma cells were co-cultured with 3 x 105
(3500 rad) irradiated syngeneic splenic APCs in the presence of indicated stimuli for 24
hr. Purified CD3 antibody was pre-mounted in positive control wells. Culture supernatant
was harvested for IL-2 ELISA assay (BD PharMingen). Purified anti-IL-2 capture
antibody (clone MQ1-17H12) was diluted to 2μg/ml in binding solution. 100 μl of the
diluted antibody solution was added per well of a 96-well ELISA plate (Nunc Maxisorb).
The plate was sealed and incubated overnight at 4°C. The capture antibody solution was
discarded, and non-specific binding was blocked by adding 200μl of blocking buffer per
well (BD Bioscience), and incubated at RT for at least 2hrs. After wash with PBS/Tween
(PBS and 0.1% Tweens) for 3 times, 100μl of culture supernatants were added to the each
sample well, meanwhile a series of nine 2-fold dilutions of recombination mouse IL-2
standard (from 5000pg/ml to 19.5pg/ml) was added to standard curve wells. The plate
was sealed and incubated at 4°C overnight. After washing with PBS/Tweens for 4 times,
100μl diluted biotinylated anti-IL-2 detection antibody (1μg/ml) was added and incubated
at RT for 1 hour. Again after washing with PBS/Tween for 4 times, 100μl diluted
peroxidase labeled anti-biotin (Vector laboratories, Burlingame, CA) was added and
incubated at RT for 30 minutes. The plate was washed for 5 times and 100ul of ABTS
substrate solution with hydrogen peroxide was added for color development. After color
developed for 5-10 min, the optical density value was read on a microplate reader
instrument (Bio-Rad) setting to 405nm.
5’RACE
T cells were isolated from the CNS of TCRβ1 retrogenic mice with disease scores
≥ 3. RNA was isolated and 5’ RACE performed using the 5'/3' RACE Kit, 2nd
Generation (Roche, Indianapolis, IN) following the manufacturer’s instructions. Briefly,
full strand cDNA was synthesized from mRNA by using specific primer 1 (5’GGAGTCAAAGTCGGTGAACAG-3’). The mRNA template was degraded by
Transcriptor Reverse Transcriptase. PolyA was added to the 3’ end of the cDNA, and the
tailed cDNA was PCR amplified using the Oligo (dT) anchor primer (5’GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTV-3’) and a nested specific
primer 2 (5’-CCTGAGACCGAGGATCTTTTAAC-3’). A second PCR reaction was
performed with the PCR anchor primer (5’-GACCACGCGTATCGATGTCGAC-3’) and
a nested specific primer 3 (5’-CAGGTTCTGGGTTCTGGAT-3’). PCR products were
subsequently cloned with TOPO TA (Invitrogen). Bacterial clones were randomly
selected for Sanger sequencing, and sequences identified using the IMGT database
(http://www.imgt.org/).
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Statistics
Means and SDs were calculated in Excel or PRISM. Plots demonstrate mean ±1
SD. Two-tailed student t-tests were applied to compare any two groups and ANOVA for
three or more groups. For multiple comparisons, significance is only shown for indicated
groups. A p < 0.05 was considered statistically significant. Kaplan Meier curves were
calculated in PRISM.
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CHAPTER 3.

RESULTS

Introduction
Despite the theoretical diversity of the TCR repertoire, a small fraction of  and 
monomers are shared by most individuals, or public42,44. Public TCR largely result from
recombinatorial biases in TCR  and  chain formation, and in some studies were found
to be prevalent in autoimmune and other responses43,124-126. Unlike antibodies, which can
engage antigens in highly variable manners, TCR heterodimers associate with pMHC
in largely stereoptypical orientations that require significant energy contributions from
both the TCR  and  chains6. Considering this, public TCR  or  chains would not be
expected to bias TCR recognition, as each public  or  may associate with a vast array
of distinct  or  chains that contribute roughly equally to recognition. However, it has
also been shown that certain TRAV and TRBV chains are preferentially employed in
specific responses38-41, and in one case structural data identified a binding “hotspot”
between a single TRBV and antigen-MHC ligand explaining this preference124.
Considering this, we hypothesized that public  or  chains, which are fixed not
only for the V region, but for J and CDR3 sequences may modulate a TCR
heterodimer’s likelihood of productively engaging autoantigen. Because public TCR
chains are shared throughout a population and, due to their preferential formation, often
present at high frequency127, they may in theory also broadly influence autoimmune
susceptibility.
Here we use a model of CNS autoimmune disease, experimental autoimmune
encephalomyelitis, to identify the role of public TCR chains in disease susceptibility,
coupling high-throughput analyses of the TCR repertoire with functional studies and the
transgenic expression of 15 disease-associated public and private TCR. Analyses of >18
million TCR from Foxp3+ regulatory and Foxp3- conventional T cells from different
organs and time points identified a high prevalence of public TCR within the
autoimmune response, consistent with previous lower resolution analyses in other
models.
Results
High Prevalence of Public TCR in the Autoimmune Repertoire
Demographic information of the sequenced TCRrepertoires
To understand the composition and dynamics of autoimmune effector and
regulatory repertoires, we analyzed CD4+ Foxp3- (Tconv) and Foxp3+ (Treg) TRBV13-2+
TCR in mice with myelin oligodendrocyte glycoprotein (MOG)35-55-induced EAE and
healthy controls. TRBV13-2 is the dominant TCR in MOG-specific T cells128.
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Saturation sequencing was performed using high-throughput techniques, with >18x106
TCR studied43,102,117,129,130, either from control mice (Table 3-1), EAE immunized mice
with early disease (Table 3-2) or EAE immunized mice with late disease (Table 3-3).
TRBJ utilization
TRBJ utilization, an indicator of the heterogeneity of the sequenced populations,
was compared in Tconv and Treg from the CNS and spleens of mice with EAE and
spleens of controls and analyzed by one-way ANOVA. The results demonstrated that
TRBJ utilization was diverse and similar among these sample groups, not matter the
comparison was for unique sequences, which represented clonotype diversity, or total
sequences, which represented both diversity and abundance. Only a slightly increased
frequency for TRBJ 2.1 usage was seen in Tconv and Treg from the CNS with early EAE
(Figure 3-1).
CNS infiltrating TCR repertoires mapped onto splenic TCR repertoire
When we performed routine phenotypic staining on the CNS infiltrating T cells,
we found the majority of CNS infiltrating Tconv cells had activated, memory/effector T
cell phenotype with high level CD69 and CD44 expression. Therefore we tried to trace
the cell origin by comparing the TCR repertoires of CNS Tconv cells with the splenic
memory and naïve TCR repertoires. The results demonstrated that the splenic sequences
identified in the CNS were heavily biased toward the memory/activated subset
(77.7±9.0% of unique, 99.0±0.7% of total TCR sequences acquired) (Figure 3-2),
indicating that the CNS was infiltrated by highly diverse, activated T cell populations
from the periphery.
Over representation of shared TRBV13-2+ TCR among CNS-infiltrating T
cells
Due to the limited size of the CNS infiltrates, relatively small numbers of unique
sequences were identified in the CNS repertoires (Table 3-2 and Table 3-3). Of these,
9.2% of the unique Foxp3- CNS sequences present in mice with early EAE (d 15-18)
were shared by ≥2 of 9 mice (Figure 3-3a). However, the shared sequences comprised
50.8% of total CNS sequences acquired, indicating a high prevalence of the shared
TCR. Similarly, in 3 mice analyzed with late disease (d 26), 8.1% of unique sequences
were shared, but these comprised 49.6% of total CNS Foxp3- sequences (Figure 3-3d).
Progressively smaller numbers of unique Foxp3- TCR were shared in the CNS by
increasing numbers of mice (Figure 3-3b, e). Meanwhile, we noticed the shared TCR
had a pattern to be over-represented due to clonal expansion. For example, 0.05% of
unique CD4+ Foxp3--derived TCRsequences were identified in ≥7 of the 9 early EAE
CNS, but comprised >1.5% of total sequences acquired. Therefore, we calculated the
frequency of identification of each unique amino acid sequence relative to that of an
average sequence in the same CNS. The representation ratio increased along with the
increasing number of shared mice, suggesting these shared TCR were heavily utilized
(Figure 3-3c, f). A similar pattern of high shared TCR representation was evident with
CNS-infiltrating Treg cells (Figure 3-3g-l).
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Table 3-1.
mice.
Mouse

Description of TRBV13-2+ TCR sequences acquired from control
Organ

Cell type

Total
sequences
acquired

Unique
Unique
CDR3 aa
CDR3 nt
sequences
sequences
acquired
acquired
1
Spleen
Foxp3
281,344
73,570
106,280
Spleen
Foxp3+
440,281
23,277
29,429
2
Spleen
Foxp3
62,062
27,752
36,092
Spleen
Foxp3+
111,605
14,542
17,415
3
Spleen
Foxp3
290,060
66,792
94,807
Spleen
Foxp3+
270,998
19,853
24,702
+
lo
Thymus
CD4+CD8 TCR
256,784
61,634
76,304
4
Spleen
Foxp3438,870
52,958
74,596
Spleen
Foxp3+
351,528
24,441
31,038
+
lo
Thymus
CD4+CD8 TCR
393,817
75,945
95,070
5
Thymus
CD4+CD8+TCRlo
216,474
47,159
58,864
+
lo
6
Thymus
CD4+CD8 TCR
280,972
52,659
65,831
Splenocytes were flow sorted for CD4, TCR and GFP-Foxp3 as indicated. The
CD4+CD8+TCRlo thymic population was CD5 and CD69 negative, indicative of a preselection population. Numbers listed are of sequences available for analysis after culling
based on sequence quality metrics.
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Table 3-2.
early EAE.

Description of TRBV13-2+ TCR sequences acquired from mice with

Mouse

EAE
day

Disease Organ
score

1

15

3

2

15

3

3

16

3

4

16

3

8

18

3

9

18

2

10

15

3

Cell type

Total
sequences
acquired

CNS
CNS
Spleen
Spleen
CNS
CNS

Foxp3Foxp3+
Foxp3Foxp3+
Foxp3Foxp3+

Spleen
Spleen
CNS
CNS
Spleen
Spleen
CNS
CNS
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
CNS
CNS
Spleen

Foxp3Foxp3+
Foxp3Foxp3+
Foxp3Foxp3+
Foxp3Foxp3+
Foxp3Foxp3+
Foxp3Foxp3+
Foxp3Foxp3+
Foxp3Foxp3+
CD45Rbhi
CD44loFo
xp3CD45Rblo
CD44hiFo
xp3Foxp3+
Foxp3Foxp3+
CD45Rbhi
CD44loFo
xp3CD45Rblo
CD44hiFo
xp3Foxp3+
Foxp3-

Spleen

11

15

4

Spleen
CNS
CNS
Spleen
Spleen

12

18

3

Spleen
CNS
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156,144
87,181
63,835
24,836
46,981
49,642

Unique
CDR3 aa
sequences
acquired
2,874
4,132
29,305
6,735
2,449
1,439

Unique
CDR3 nt
sequences
acquired
3,421
4,713
38,439
7,580
2,728
1,658

97,675
867,145
103,407
82,018
77,028
71,488
186,996
264,020
388,207
53,833
380,377
421,907
327,583
315,408
274,619
87,560
304,477

37,439
18,941
3,513
2,664
30,955
11,741
3,497
3,417
55,115
6,701
50,920
17,770
62,579
15,389
2,687
2,240
41,969

52,648
24,258
3,999
3,138
39,967
13,828
4,041
4,189
78,185
7,545
70,037
22,336
89,502
19,027
3,506
2,628
57,395

39,229

4,961

5,527

310,883
591,007
53,291
135,721

11,828
1,700
911
31,439

14,484
2,261
1,073
41,642

396,380

10,393

12,541

133,339
109,483

10,502
1,410

12,490
1,726

Table 3-2.
Mouse

EAE
day

(Continued).
Disease Organ
score

Cell type

Total
sequences
acquired

Unique
CDR3 aa
sequences
acquired
1,508
35,012

Unique
CDR3 nt
sequences
acquired
1,857
47,045

Foxp3+
88,279
hi
CD45Rb
133,687
CD44loFo
xp3Spleen
CD45Rblo 192,803
12,083
14,474
hi
CD44 Fo
xp3Spleen
Foxp3+
317,907
14,737
18,525
13
18
4
CNS
Foxp3288,981
1,429
1,915
CNS
Foxp3+
42,867
1,172
1,362
hi
Spleen
CD45Rb
335,855
65,789
95,606
CD44loFo
xp3Spleen
CD45Rblo 225,451
11,932
14,176
hi
CD44 Fo
xp3Spleen
Foxp3+
290,023
14,003
17,136
14
18
4
CNS
Foxp3224,925
3,240
4,061
CNS
Foxp3+
385,327
4,077
5,305
hi
Spleen
CD45Rb
304,862
46,495
64,598
CD44loFo
xp3Spleen
CD45Rblo 351,771
16,385
20,123
hi
CD44 Fo
xp3Spleen
Foxp3+
464,759
19,879
25,604
Cells were flow sorted for CD4, TCR, and, as indicated, GFP-Foxp3, CD45Rb, and
CD44.
CNS
Spleen
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Table 3-3.
late EAE.
Mouse

Description of TRBV13-2+ TCR sequences acquired from mice with

EAE
day

Disease
score

Organ

Cell type

Unique
Unique
CDR3 aa CDR3 nt
sequences sequences
acquired acquired
5
26
1
CNS
Foxp3
12,038
1,322
1,399
CNS
Foxp3+
25,388
3,097
3,362
Spleen
Foxp3
291,902
61,300
90,429
Spleen
Foxp3+
299,258
13,610
16,711
6
26
2
CNS
Foxp3
40,212
3,629
4,039
CNS
Foxp3+
130,450
9,942
11,581
Spleen
Foxp3
2,735,563 140,052
220,739
Spleen
Foxp3+
123,832
15,375
18,333
7
26
3
CNS
Foxp348,451
3,455
3,776
+
CNS
Foxp3
1,439
809
828
Spleen
Foxp31,247,903 88,487
132,053
+
Spleen
Foxp3
177,834
11,042
12,892
Cells were flow sorted for CD4, TCR and the presence or absence of GFP-Foxp3.

24

Total
sequences
acquired

Figure 3-1. TCR TRBJ use during EAE.
TRBV13-2+ TCR repertoires were determined in the spleens of pre-immune mice (n=4)
and spleens and CNS of mice with early (d 15-18, n=9) or late (d 26, n=3) EAE. TRBJ
use was tabulated for acquired sequences as an indicator of repertoire diversity. Mean+1
s.d. percent of unique (a, b) or total (c, d) TRBJ use by CD4+GFP-Foxp3- (a, c) and
CD4+GFP-Foxp3+ (b, d) derived TCR from individual mice is plotted.
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Figure 3-2. Association of CNS TCR with the memory T cell pool.
CNS TCR sequences from sorted CD45RbhiCD44lo or CD45RbloCD44hi T cells from
the spleens of the same mice (n=5) were compared to determine the association of CNSinfiltrating sequences with the naïve and memory populations. (a) Percent of unique CNS
sequences that were identified exclusively in the splenic memory or naïve populations, or
in both memory and naïve populations are plotted. (b) Percent of total CNS sequences
acquired were mapped as in (a).
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Figure 3-3. Representation of shared TRBV13-2+ TCR among CNS-infiltrating
T cells.
CNS TRBV13-2+ Tconv and Treg TCR repertoires from mice with early (d 15-18, n=9;
a-c, g-i) or late (d 26, n=3, d-f, j-l) EAE were determined by high-throughput sequencing.
(a, d, g, j) The proportion of unique TCR amino acid sequences and total TCR
sequences acquired that were cumulatively identified in the indicated number of mice is
plotted. (b, e, h, k) The number of unique amino acid sequences shared in the CNS of the
indicated number of mice with early or late EAE is plotted. (c, f, i, l) The frequency of
identification of each unique amino acid sequence relative to that of an average sequence
in the same CNS, was calculated. The mean of this, or representation ratio, for sequences
shared by the indicated number of mice with early or late EAE is plotted.
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Preferential deployment of public versus private TCR to the autoimmune
repertoire
The prevalence of the shared TCR in the CNS repertoire did not indicate that
shared sequences were preferentially employed. Public sequences uninvolved in the
autoimmune response may have been present at similarly high frequencies, leading to
their proportionately high utilization131. There, TCR from cells involved and uninvolved
in the CNS response could be directly compared. We proposed one model that if TCR
engaged in the CNS response were randomly deployed from the public and private
peripheral repertoires, then splenic sequences identified and not identified in the CNS
would be expected to be similarly public (Figure 3-4 Model 1). We also proposed an
alternative model that if public TCR were preferentially incorporated into the CNS
response, the splenic sequences also seen in the CNS should be enriched in public
sequences (Figure 3-4 Model 2).To assess this and establish the extent to which CNSinfiltrating T cells are public, we analyzed the more abundant TCR sequences in the
spleen.
EAE splenic TCRmapped onto CNS TCRrepertoires
To test our hypothesized models, we were able to map the splenic
TCRsequences from the mice with EAE onto CNS TCRrepertoires. Splenic TCR
sequences also seen in the CNS were markedly more likely to be shared than sequences
not observed in the CNS. For example, 28.5% of the unique CNS Foxp3- sequences from
mice with early disease were identified in all spleens analyzed compared with 2.7% of
non-CNS sequences, indicating that many CNS sequences are derived from the public
repertoire (Figure 3-5a). Pairwise analysis of the sharing of CNS and non-CNS
sequences between individual mice verified this finding (Figure 3-5c). Results were
similar in mice with late disease (Figure 3-5b, c) and for Foxp3+ T cells (Figure 3-5d-f).
When we analyzed the total splenic TCR sequences, the results above
enumerating unique TCR sequences acquired was replicated tabulating, and this also
showed a dramatically enhanced sharing of CNS compared with non-CNS sequences
(Figure 3-6).
Over-representation of CNS T cell-associated TCR in the pre-immune
public repertoire
Our previous analysis of the preferential recruitment and expansion of public
splenic T cells was derived from the context of CNS inflammation. To circumvent the
distortion from immune responses, we proposed that CNS infiltrating TCR should be
disproportionately public in pre-immune mice too. To test this, we mapped splenic TCR
sequences from mice with EAE onto pre-immune repertoires. For all samples analyzed,
either Foxp3- or Foxp3+ and early or late disease, substantially more CNS-infiltrating
than non-infiltrating TCR sequences were identified as public in the pre-immune
repertoire (Figure 3-7). This again was true both for unique and total TCR sequences
analyzed. Together, these data support a heavily biased public TCR usage in the EAE
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Figure 3-4. Models for the high frequency of shared CNS TCR.
In model 1, the high frequency of shared CNS TCR is explained by a generally high
frequency of public relative to private TCR. In this model, T cells are randomly
recruited to and expand within the autoimmune repertoire. Splenic TCR that are present
within the CNS repertoire will show similar proportions of public sequences as TCR
that are uninvolved in the autoimmune process. In model 2, public TCR are
disproportionately recruited to and/or expand within the autoimmune response. In this
case, there is a greater representation of public TCR among splenic sequences identified
within the CNS than those unassociated with CNS autoimmunity.
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Figure 3-5. Over-representation of unique public sequences in the CNSinfiltrating repertoire.
Splenic CD4+ GFP-Foxp3- and GFP-Foxp3+ TRBV13-2+ TCR repertoires from mice
with early (d 15-18; n=4) or late (d 26; n=3) EAE were segregated into sequences
identified or not within the CNS. Percent of unique TCR sequences that were shared by
the indicated number of mice with early (a, d) and late (b, e) disease is shown. (c, f) The
overlap of the repertoire from each mouse was compared pairwise with that of every
other mouse in a cohort.
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Figure 3-6. Over-representation of total public sequences in the CNS-infiltrating
repertoire.
Analyses were performed on the same data sets as in Figure 3-5, however overlap among
total, rather than unique, TCR sequences acquired was assessed. For this, frequencies
were normalized so total sequence number was effectively equal in each mouse. This
ensured that the weighting of each mouse in calculations was equivalent. Percent of total
TCR sequences that were shared by the indicated number of mice with early (a, d) and
late (b, e) disease is shown. (c, f) The overlap of the repertoire from each mouse was
compared pairwise with that of every other in a cohort.
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Figure 3-7. Over-representation of unique and total CNS-associated Foxp3+ and
Foxp3- public TCR in the pre-immune repertoire.
Splenic TRBV13-2+ TCR amino acid repertoires from CD4+GFP-Foxp3- and GFPFoxp3+ T cells of mice with early (d 15-18; n=4) or late (d 26, n=3) EAE were mapped
onto the splenic CD4+GFP-Foxp3- or CD4+GFP-Foxp3+ repertoires from pre-immune
mice (CTRL; n=4). Percent of unique CD4+GFP-Foxp3- sequences that were or were not
identified in the CNS from mice with early (a) or late (b) EAE and also present in the
CD4+GFP-Foxp3- repertoires of the indicated number of pre-immune spleens is plotted.
(c) As in (a, b), but the overlap of repertoires from individual mice with EAE and
individual pre-immune mice is plotted. (d-f) Analyses are equivalent to (a-c), but
assessing unique sequence overlap between CD4+GFP-Foxp3+ repertoires. (g-l) Parallel
analyses of total CD4+GFP-Foxp3- and CD4+GFP-Foxp3+ sequences acquired from mice
with early or late EAE and pre-immune mice. As in Figure 3-5, sequence events were
normalized for comparisons of total sequence overlap between mice, effectively
equalizing the total number of sequences in each mouse.
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repertoire, with this preference traceable to the pre-immune repertoire.
Temporal focusing of the public TCR repertoire
To determine whether the extent of sharing of autoimmune repertoires differed in
early and late EAE, we next compared CNS repertoires from individual mice. Overlap of
CNS sequences was lowest when pairs of d 15-18 mice were compared with each other.
Repertoire overlap increased when d 15-18 mice were compared with d 26 mice, and was
greatest when d 26 mice were compared (Figure 3-8a, b). Splenic TCR overlap, unlike
that of CNS TCR, did not change with disease stage (Figure 3-8c, d). Therefore the
extent of sharing increases specifically with time in the disease-associated repertoire.
That mice with early disease shared more of their CNS repertoire with late disease mice
than with each other further indicates a temporal focusing of the shared CNS repertoire.
Recombinatorial bias and oligoclonality in autoimmune repertoire formation
Considering the relatedness of the d 15-18 and d 26 repertoires, we combined the
12 CNS data sets we acquired to identify common TCR sequences. Forty eight TCR
were identified in ≥10 of the 12 CNS repertoires (Table 3-4). These receptors were
oligoclonal with multiple nt sequences used for each CNS amino acid sequence
cumulatively (range 2-59, median=13) and within single mice (mean 2.8±1.3). Consistent
with their oligoclonal presence, in individual CNS 46.7±19.9% of the 48 public TCR
were identified in both the Foxp3+ and Foxp3- lineages compared with 2.9±1.9% of
private sequences (p<10-5).
Biased rearrangement of public TCR in the thymus of pre-immune mice
Given that the prevalence of CNS public sequences can be traced into splenic
repertoire of pre-immune mice. We questioned whether these public TCR originated
from the thymus with high probability of forming. Indeed, public TCR have been
proposed for a high probability of forming in the thymus due to a process called biased
recombination44,132,133. To assess this in the autoimmune public repertoire, we analyzed
pre-selection CD4+CD8+TCRlo (DP) repertoires in pre-immune mice131. Nucleotide
sequence diversity of each of the 48 public TCR was compared with that of paired
private TCR from the same mouse with identical V, J and CDR3 length, and similar
identification frequencies (>0.25 – <4 fold). The public sequences displayed markedly
greater pre-selection nt variability than control private sequences (6.2±2.9 vs 1.1±0.1 nt
sequences) (Figure 3-9), indicating that these have an increased probability of forming
and the pre-selection recombinatorial biases foster disease-associated public repertoire
formation.
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Figure 3-8. Repertoire focusing in mice with EAE.
CNS TCR repertoires of CD4+GFP-Foxp3- and Foxp3+ T cells were compared between
individual mice with early and late disease to determine changes in the overlap between
repertoires with disease progression. Percent CNS CD4+GFP-Foxp3- (a) and Foxp3+ (b)
CNS TCR repertoire overlap between individual mice with early disease, mice with
early versus late disease, and mice with late disease is plotted. Comparable analyses were
performed on splenic CD4+GFP-Foxp3- (c) and CD4+GFP-Foxp3+ (d) TCRrepertoires.
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Table 3-4.

Highly shared CNS CDR3 sequences.

CDR3 sequence

CNS
shared

CNS
shared
(Foxp3-)
12

CNS
shared
(Foxp3+)
12

Mean
(%)

Foxp3Median
(%)

0.986

0.235

ASGETGGNYAEQF

12

ASGQDTQY

12

10

11

0.086

0.014

ASGDRYEQY

12

12

8

0.248

0.221

ASGEYEQY

12

7

11

0.102

0.008

ASGDNYNSPLY

12

8

10

0.015

0.009

ASGDAGNTLY

12

7

10

0.093

0.020

ASGDSYNSPLY

11

9

10

0.182

0.024

ASGEDTQY

11

11

7

0.299

0.015

ASGYEQY

11

8

9

0.013

0.009

ASGETANSDYT

11

6

10

0.019

0.006

ASGDSSGNTLY

11

7

9

0.006

0.006

ASGEAGGNYAEQF

11

7

9

0.003

0.002
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Range
(%)

Mean
(%)

Foxp3+
Median
(%)

(0.0175.375)
(<0.0010.591)
(0.0080.626)
(0.0010.605)
(<0.0010.060)
(<0.0010.351)
(0.0051.359)
(<0.0013.081)
(0.0020.044)
(0.0010.087)
(<0.0010.017)
(<0.0010.009)

1.818

1.774

0.150

0.018

0.047

0.009

0.166

0.069

0.061

0.008

0.158

0.089

0.061

0.010

0.029

0.012

0.609

0.047

0.872

0.592

0.140

0.019

0.086

0.009

Range
(%)
(0.0084.346)
(0.0020.978)
(0.0010.290)
(0.0060.940)
(<0.0010.281)
(0.0020.772)
(0.0010.221)
(0.0020.139)
(0.0095.187)
(0.0013.136)
(<0.0010.503)
(0.0010.662)

Table 3-4.

(Continued).

Mean
(%)

Foxp3Median
(%)

0.534

0.082

8

0.008

0.003

10

9

0.084

0.010

10

8

10

0.217

0.059

ASGDDEQY

10

10

8

0.065

0.010

ASGDAGYEQY

10

8

9

0.033

0.025

ASGDEQY

10

8

9

0.009

0.003

ASGDQDTQY

10

9

8

0.014

0.006

ASGDAETLY

10

6

10

0.016

0.006

ASGGTGGNYAEQF

10

6

10

0.003

0.001

ASGDAGGYEQY

10

8

8

0.013

0.015

ASGDWGSAETLY

10

8

8

0.016

0.006

CDR3 sequence

CNS
shared

CNS
shared
(Foxp3-)
7

ASGDAGNSDYT

11

ASGDRGYEQY

11

6

ASGDNSGNTLY

10

ASGDAGGSYEQY

CNS
shared
(Foxp3+)
8
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Range
(%)

Mean
(%)

Foxp3+
Median
(%)

(0.0023.315)
(0.0010.033)
(<0.0010.577)
(0.0011.221)
(<0.0010.481)
(0.0040.103)
(0.0010.033)
(<0.0010.042)
(0.0010.059)
(<0.0010.013)
(<0.0010.030)
(0.0010.050)

0.065

0.023

0.164

0.039

0.119

0.054

0.067

0.040

0.091

0.010

0.176

0.073

0.189

0.045

0.050

0.013

0.104

0.019

0.099

0.048

0.069

0.068

0.031

0.006

Range
(%)
(0.0010.175)
(0.0010.583)
(<0.0010.664)
(0.0010.225)
(<0.0010.352)
(0.0010.860)
(0.0101.091)
(0.0020.267)
(<0.0010.619)
(0.0020.343)
(<0.0010.219)
(<0.0010.169)

Table 3-4.

(Continued).

CDR3 sequence

CNS
shared

CNS
shared
(Foxp3-)
7

CNS
shared
(Foxp3+)
8

Mean
(%)

Foxp3Median
(%)

0.143

0.008

ASGPYEQY

10

ASGDSAETLY

10

8

7

0.007

0.008

ASGDSYEQY

10

8

7

0.037

0.013

ASGGTGGYEQY

10

9

6

0.035

0.008

ASGDRGNTEVF

10

7

8

0.031

0.002

ASGDRGSGNTLY

10

9

6

0.027

0.005

ASGDADTQY

10

7

7

0.042

0.030

ASGGGQNYAEQF

10

9

5

0.054

0.038

ASGDAGSQNTLY

10

6

8

0.013

0.012

ASGDAGEQY

10

8

6

0.019

0.008

ASGDAGGQNTLY

10

7

7

0.006

0.004

ASGDGYEQY

10

7

7

0.004

0.003
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Range
(%)

Mean
(%)

Foxp3+
Median
(%)

(0.0010.913)
(0.0010.017)
(0.0010.123)
(0.0010.204)
(0.0010.134)
(0.0010.130)
(<0.0010.149)
(0.0020.143)
(0.0020.024)
(<0.0010.091)
(<0.0010.017)
(0.0010.008)

0.277

0.043

0.146

0.032

0.018

0.012

0.020

0.011

0.011

0.002

0.014

0.003

0.017

0.001

0.005

0.003

0.045

0.017

0.028

0.008

0.030

0.027

0.031

0.006

Range
(%)
(0.0011.681)
(<0.0010.659)
(0.0010.069)
(0.0020.069)
(<0.0010.070)
(<0.0010.069)
(0.0010.059)
(0.0020.012)
(0.0010.179)
(0.0010.112)
(0.0020.073)
(0.0010.143)

Table 3-4.

(Continued).

Mean
(%)

Foxp3Median
(%)

0.014

0.005

6

0.005

0.004

5

8

0.020

0.006

10

8

5

0.011

0.007

ASGDAWGGYEQY

10

5

8

0.049

0.041

ASGEGTGGYEQY

10

8

5

0.060

0.009

ASGDNYEQY

10

8

5

0.005

0.003

ASGDAGTGGYEQY

10

8

5

0.013

0.005

ASGEQGYEQY

10

5

7

0.180

0.002

ASGDGGNQDTQY

10

8

4

0.045

0.028

ASGDWGSSYEQY

10

5

6

0.089

0.008

ASGGQNTEVF

10

6

5

0.002

0.002

CDR3 sequence

CNS
shared

CNS
shared
(Foxp3-)
6

ASGDPGGYEQY

10

ASGDAGGQDTQY

10

8

ASGDVEQY

10

ASGDEDTQY

CNS
shared
(Foxp3+)
8

39

Range
(%)

Mean
(%)

Foxp3+
Median
(%)

(0.0010.062)
(<0.0010.015)
(<0.0010.079)
(0.0010.033)
(0.0020.125)
(<0.0010.311)
(0.0010.017)
(0.0010.052)
(0.0010.700)
(0.0080.167)
(0.0010.376)
(<0.0010.005)

0.016

0.009

0.020

0.011

0.105

0.026

0.084

0.005

0.040

0.009

0.002

0.001

0.016

0.006

0.005

0.003

0.028

0.008

0.004

0.005

0.039

0.016

0.018

0.004

Range
(%)
(0.0010.069)
(0.0010.078)
(<0.0010.386)
(0.0010.325)
(0.0010.210)
(<0.0010.008)
(0.0020.048)
(0.0010.015)
(0.0010.140)
(0.0010.008)
(<0.0010.168)
(0.0010.043)

Table 3-4.

(Continued).

Sequences for 48 TRBV13-2+ CDR3 from TCR identified as highly shared in the CNS are listed. The number of mice in which the
sequences were identified (n=12 total) in Foxp3- and Foxp3+ T cells is listed, as is the mean, median, and range of the percent of total
CNS sequences acquired with the indicated amino acid sequence.
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Figure 3-9. Formation of the public autoimmune TCR repertoire through biased
recombination.
To determine the diversity of the public autoimmune repertoire in pre-selection
thymocytes, nucleotide (nt) sequences identified for 48 highly public CNS TCR amino
acid sequences were assessed in sorted pre-selection CD4+CD8+TCRlo thymocytes from
healthy mice (n=4). The mean number of unique nt sequences per thymus for each of the
48 sequences is plotted. For each CNS sequence, paired control private sequences were
identified in each mouse with the same TRBV, TRBJ, and CDR3 length, and similar
frequency (>0.25-<4 fold) as the public sequence for comparison. Mean unique nt
sequences is similarly plotted.
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Functional Characterization of the CNS Public TCRin Retrogenic Mice Model
Spontaneous autoimmunity mediated by a public TCR
Autoantigen-specific T cells are readily identifiable in the T cell repertoire of
healthy individuals133-135. The preferential use of public TCR during EAE suggested a
role for direct evidence. To better define the impact of public TCR, we generated
retroviral transgenic (retrogenic) mice that enforced the expression of the most common
public TCRsequence, TCR1 (Table 3-5)101,123,136.
Phenotypic characterization of TCR1 retrogenic mice
Impressively, TCR1 retrogenic mice developed spontaneous EAE with very
early T cell engraftment at ~4 wk (Figure 3-10a). Indeed, numbers of T cells infiltrating
the CNS at this time were similar to numbers in the spleen (Figure 3-10b). CD4+Foxp3-,
CD4+Foxp3+, and CD8+ T cells engrafted (Figure B-2, B-3), and the CD69 activation
marker was expressed on 31±5% and 81±5% of splenic and CNS T cells from diseased
mice respectively (Figure 3-10a-d, Figure B-2). Mortality was >50% (Figure 3-10a).
TCR1+ T cells proliferated strongly to MOG35-55 and CNS and splenic cells
demonstrated Th1 and Th17 subset differentiation and a histologic pattern consistent with
optico-spinal encephalomyelitis (Figure 3-10c-f, Figure 3-11e-g). Notably, disease in
mice retrogenic for just the TCR1 monomer was markedly accelerated, increased in
incidence, and more severe than our prior results with retrogenic mice expressing five
different disease-associated private MOG-specific TCR heterodimers101.
TCR1 imposes MOG35-55 specificity on TCR heterodimers
TCR1 retrogenic mice were enforced to express a single TCRchain (TCR
pairing with endogenous random TCRchainshe corresponding TCR repertoire would
be limited but diverse enough for a wide spectrum of TCR specificity. Referred to our
observation, we hypothesized that single TCR1might dominate MOG35-55 recognition on
TCR with diverse TCR. To establish pairing requirements, we co-expressed TCR1
with 7 TCR chains isolated from non-TCR1 TCR. We reconstituted the TCR
heterodimers and enforced the expression on CD4 4G4 hybridoma cell lines. In vitro,
MOG35-55 stimulation assay showed two of the hybrid TCR responded to MOG35-55,
indicating that TCR1 can drive MOG responsiveness with random TCR chain (Figure
3-12). TCR cDNA was further isolated from CNS-infiltrating T cells from 3 TCR1
mice by 5’ RACE and subcloned. These were heterogeneous and did not overlap between
mice (Table 3-6), indicating that TCR1 is associated with many TCR.
Protective role of the co-engrafted wide type (WT) cells in chimeric
retrogenic mice
To determine whether non-transgenic T cells impede spontaneous EAE mediated
by TCR1, we generated chimeric retrogenic mice, mixing wild type CD45.1+CD45.2and smaller numbers of congenic TCR1-transduced CD45.1-CD45.2+ hematopoietic
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Table 3-5.
TCR name

TCR retrogenic mice.
TRBJ

CDR3 sequence

CNS shared, Public (group 1)
2-1
ASGETGGNYAEQF
TCR1
2-7
ASGDRYEQY
TCR2
2-7
ASGYEQY
TCR3
1-2
ASGETANSDYT
TCR4
2-7
ASGDAGGSYEQY
TCR5
2-7
ASGDGEQY
TCR6
CNS non-shared, Public (group 2)
2-1
ASGEQQGTEQF
TCR7
2-7
ASGDGLGGSYEQY
TCR8
1-6
ASGDVRGYNSPLY
TCR9
1-2
ASGDGTSNSDYT
TCR10
Private (group 3)
2-5
ASGIGDTQY
TCR11
2-7
ASGDAGTGYEQYF
TCR12
2-4
ASGDWGGEDTLYF
TCR13
2-4
ASGDETGGAYEQYF
TCR14
2-3
ASGGGLGGTSAETLYF
TCR15
Control
OT-II
2-4
ASSLGGESQNTLYF

CNS
shared
(Total,
n=12)

CNS
shared
(Foxp3-)

CNS
shared
(Foxp3+)

SPL
Shared
(Total,
n=9)

SPL
shared
(Foxp3-)

SPL
shared
(Foxp3+)

12
12
11
11
10
9

12
12
8
6
8
4

12
8
9
10
10
9

9
9
9
9
9
9

9
9
9
9
9
9

9
9
9
9
9
9

1
1
1
1

1
1
0
0

1
0
1
1

3
9
2
9

3
9
1
9

1
5
1
2

1

0

1

1

1

1
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Table 3-5.

(Continued).

TRBV13-2+ TCR  chains that were shared in total, Foxp3-, and Foxp3+ populations in the CNS and spleen of the indicated number of
mice were transduced into TCR-/- HPC and retrogenic mice generated. For TCR chains identified in a single mouse, the percent of
total TRBV13-2+ TCR sequences in the CNS bearing the indicated sequence is listed in parentheses. For shared CNS sequences,
frequency means, medians, and ranges are provided in Table 3-1. Sequences 12-15 were isolated from primary TRBV13-2+ MOG3555-specific T cell hybridomas in our laboratory, and were not observed in any of the mice evaluated for the repertoire analyses here.
OT-II comprises the TCR chain from the ovalbumin 323-229-specific OT-II TCR, and was assessed as a negative control.
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Figure 3-10. Enforced public TCR expression leads to spontaneous autoimmune
encephalomyelitis.
Retrogenic mice were generated by transducing TCR-/-, GFP-Foxp3 HPCs with TCR1.
(a) Kaplan Meier analysis of survival and disease-free survival. (b) Absolute numbers of
CD4+TCR+ and CD4+TCR+GFP-Foxp3+ T cells in spleens and CNS of TCR1 mice with
EAE. (c) Proliferation of splenic T cells from TCR1 or control retrogenic mice
expressing an OT-II TCR (ovalbumin-specific)-derived  chain in response to MOG35-55
or mitogen measured by 3H-thymidine incorporation. (d) Percent of CNS-infiltrating T
cells expressing IL-17, IFN-, or both IL-17 and IFN- in the absence or presence of exvivo restimulation, as determined by intracellular cytokine staining, is plotted. (e, f)
Histologic analyses of the CNS of TCR1 retrogenic mice showing a mixed infiltrate of
lymphocytes, macrophages, and granulocytes, gliosis and perivascular cuffing in the
septum, meninges, and optic nerve (e) and white tracts of the lumbar spinal cord (f) in
day 28 TCR1 mice but not control retrogenic mice.
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Figure 3-11. Characterization of spontaneous EAE development in TCR1
retrogenic mice.
Percent of CD4+TCR+ and CD8+TCR+ T cells within the lymphocyte gate in day 30-35
TCR1 mice in the spleen (a) and CNS (b). ****, p<0.0001. (c) The percent of
CD4+TCR+ lymphocytes expressing GFP-Foxp3 in the spleens and CNS of TCR1 and
control OT-II TCR retrogenic mice is plotted. Groups are NS by ANOVA. (d) The
percent of activated CD4+TCR+ T cells was determined by CD69 activation marker
expression in the spleen and CNS and compared with results in the spleens of OT-II
TCR mice. (e) Splenic and CNS T cells from TCR1 mice with EAE were stimulated ex
vivo with mitogen and IFN- and IL-17 production measured by intracellular staining.
Representative data is shown. Summary data is provided in figure 6d. (f) Splenocytes
from TCR1 mice with EAE were stimulated with myelin MOG35-55 and secretion of the
indicated cytokines measured by bead array. (g) Major organs from TCR1 mice with
EAE were analyzed histologically. Inflammation was localized to the CNS. Scoring of
the indicated CNS regions was performed by a blinded reviewer as described under
Methodology.
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Figure 3-12. TCR1+ TCR recognize MOG35-55.
To determine the pairing requirements of the TCR1 chain for MOG35-55 recognition, we
linked to it 7 TCR chains derived from alternative (non-TCR1) TCR in polycistronic
retroviral constructs. TCR chains and TCR1 were separated by the T. asigna 2A
sequence to support stoichiometric production of each chain, and cloned into the IRESGFP retroviral vector. Retrovirus was transduced into 4G4 TCR-deficient cells that we
had transfected to express CD4. TCR+ cells were flow cytometrically sorted, and
stimulated with MOG35-55 or anti-CD3. IL-2 production was measured by ELISA at 24
hr. (a) TCR chains that when paired with TCR1 conferred MOG35-55 responsiveness.
(b) TCR chains that did not confer MOG35-55 responsiveness.
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Table 3-6.
Distinct TCR chains isolated from CNS CD4+GFP-Foxp3+ and GFPFoxp3- T cells from TCR1 mice with EAE.
Mouse

Source

5’RACE clones:
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
2
CNS
2
CNS
2
CNS
2
CNS
2
CNS
2
CNS
3
CNS
3
CNS
3
CNS
3
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS
1
CNS

Cell
type

TRAV

TRAJ

CDR3

Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3Foxp3+
Foxp3+
Foxp3+
Foxp3+
Foxp3+
Foxp3+
Foxp3+
Foxp3+
Foxp3+
Foxp3+
Foxp3+

TRAV13-2
TRAV13D-1
TRAV14-2
TRAV14D-3
TRAV4D-3
TRAV4D-4
TRAV4D-4
TRAV4N-3
TRAV6D-6
TRAV7-1
TRAV7-2
TRAV7-3
TRAV7-4
TRAV7-4
TRAV7-6
TRAV8-1
TRAV9N-2
TRAV9N-2
TRAV9N-3
TRAV12-2
TRAV14D-1
TRAV6-2
TRAV6-3
TRAV7-4
TRAV7-4
TRAV19
TRAV4D-3
TRAV7-3
TRAV7D-3
TRAV13D-1
TRAV4D-3
TRAV4D-3
TRAV4D-4
TRAV4D-4
TRAV4N-3
TRAV7-2
TRAV7-3
TRAV7-3
TRAV7-4
TRAV7D-3

TRAJ26
TRAJ37
TRAJ26
TRAJ31
TRAJ49
TRAJ42
TRAJ57
TRAJ27
TRAJ57
TRAJ21
TRAJ23
TRAJ34
TRAJ12
TRAJ21
TRAJ33
TRAJ39
TRAJ35
TRAJ35
TRAJ39
TRAJ33
TRAJ57
TRAJ17
TRAJ45
TRAJ9
TRAJ9
TRAJ24
TRAJ21
TRAJ27
TRAJ37
TRAJ39
TRAJ50
TRAJ42
TRAJ57
TRAJ57
TRAJ47
TRAJ9
TRAJ22
TRAJ22
TRAJ12
TRAJ22

CAPPAHAQGLTF
CALITGNTGKLIF
CAARTYAQGLTF
CAARKNSNNRIFF
CAAVTGYQNFYF
CAASGGSNAKLTF
CAAGQGGSAKLIF
CAAGGYTGKLTF
CALGDRGSAKLIF
CAVRKRSNYNVLYF
CAASMDYNQGKLIF
CAVSPQSSNTNKVVF
CAASGRTGGYKVVF
CAASARSNYNVLYF
CAASNYQLIW
CATPYNNAGAKLTF
CVLSSGFASALTF
CVLSAGFASALTF
CAVSAINAGAKLTF
CALSARVNYQLIW
CAASPQNQGGSAKLIF
CVLGDRRSAGNKLTF
CAMSGADRLTF
CAAGISNMGYKLTF
CAARISNMGYKLTF
CAVPASLGKLQF
CAAGGYNVLYF
CAANTGKLTF
CAVGGNTGKLIF
CALVMNNNAGAKLTF
CAARSSSSFSKLVF
CAAGGSNAKLTF
CAAALNQGGSAKLIF
CAAGQGGSAKLIF
CAAVPMDYANKMIF
CAASWMGYKLTF
CAVSASSGSWQLIF
CAVSMSFGSWQLIF
CAASGRTGGYKVVF
CAVSISGSWQLIF
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Table 3-6.
Mouse

(Continued).
Source

Cell
TRAV
TRAJ
CDR3
type
2
CNS
Foxp3+ TRAV12-3
TRAJ39 CALRRGNAGAKLTF
2
CNS
Foxp3+ TRAV7-6
TRAJ32 CAVLGSSGNKLIF
2
CNS
Foxp3+ TRAV9D-3
TRAJ32 CALSPYGSSGNKLIF
+
2
CNS
Foxp3
TRAV9D-3
TRAJ32 CALSPYESSGNKLIF
3
CNS
Foxp3+ TRAV21
TRAJ49 CILKTGYQNFYF
+
3
CNS
Foxp3
TRAV6-5
TRAJ49 CILKTGYQNFYF
Additional TRAV4 amplification clones:
3
CNS
Foxp3+ TRAV4D-3
TRAJ33 CAAPDSNYQLIW
3
CNS
Foxp3+ TRAV4D-3
TRAJ57 CAARQGGSAELIF
+
3
CNS
Foxp3
TRAV4D-3
TRAJ40 CAAPGNYKYVF
3
CNS
Foxp3+ TRAV4D-3
TRAJ39 CAAGGDNAGAKLTF
3
CNS
Foxp3+ TRAV4D-3
TRAJ50 CAAIASSSFSKLVF
+
3
CNS
Foxp3
TRAV4D-4
TRAJ57 CAAENQGGSAKLIF
TCR were isolated by 5’RACE except for a subset of Foxp3+ clones from mouse 3 that
were isolated with TRAV4 and TCR C-specific primers.
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progenitor cells (HPCs). Approximately 40% of mice were protected from disease
(Figure 3-13a). TCR1+ cells were a minority, though less frequent in mice protected
from than developing EAE (Figure 3-13c). When EAE developed, symptoms were
milder and mortality diminished, consistent with a protective role for the co-engrafted
WT cells. We anticipated that TCR1 imposes MOG-recognition on T cells, and that this
should occur even in healthy animals. To test this, we analyzed disease-free chimeric
mice. TCR1+CD45.2+ but not WT CD45.1+ T cells from unprimed disease-free mice
proliferated strongly to MOG35-55 (Figure 3-13b, d-e). An estimated 15.6±7.8% of the
initial population of CD45.2+ T cells responded to MOG35-55 compared to 49.2±12.3% to
control CD3/CD28.
Public but not private TCR confer myelin specificity and provoke
spontaneous autoimmunity
TCR1 is to our knowledge the first example of a single TCR chain endowing a
heterogeneous population of T cells with overt spontaneous autoreactivity. To more
comprehensively define the impact of public TCR in autoimmune susceptibility, we
generated 14 additional TCR retrogenic mice using five additional TCR identified in
≥9 CNS and all spleens (group 1), four in a single CNS at high frequency and shared in
splenocytes to varying extents (group 2), and five that were wholly private (group 3;
Table 3-5). A majority of CNS-infiltrating T cells in MOG-EAE recognize the MOG35-55
epitope137. To minimize the possibility that TCR selected for analysis were derived from
non-specific bystander T cells, group 2 and 3 TCR were either derived from high
frequency CNS-infiltrating clones or private TCR sequences demonstrated to
recognize MOG35-55 autoantigen. For each TCR, mice were monitored for ≥120 days or
until the development of clinical disease, at which time all major organs were assessed
grossly and histologically. T cells from disease-free mice were assayed for MOG35-55specific responsiveness.
Of the additional group 1 TCR, none developed spontaneous EAE, though 2 of
the 5 mice showed autoimmune features. Unprimed T cells from TCR4 mice
proliferated strongly in response to MOG35-55 as measured both by 3H-thymidine
incorporation and membrane-associated dye dilution assays (Figure 3-14a-c). Therefore,
like TCR1, this TCR endows a large proportion of disparate TCR with specificity
for the MOG35-55 autoantigen. Meanwhile, T cells from TCR7 (group 2) proliferated
weakly to MOG35-55. This was detectable by 3H-thymidine incorporation but not the less
sensitive dye dilution assay (Figure 3-14d). However, mice expressing the 5 private
group 3 TCR did not show any evidence for myelin reactivity.
Notably, TCR3 T cells did not respond to MOG35-55. However, with early
engraftment these mice developed spontaneous alopecia and esophagitis (Figure 3-15).
This was associated with prominent T cell infiltrates in these locations. TCR3
implicated that some CNS-associated public TCR may provoke alternative types of
spontaneous autoimmunity. Except TCR1 and TCR3, there was no other histologic or
clinical evidence of disease in mice expressing any of the other 4 group 1 CNS public
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Figure 3-13. Spontaneous EAE was protected by the co-engrafted WT cells in
chimeric retrogenic mice.
Chimeric retrogenic mice were generated by transducing wild type (WT)
CD45.1+CD45.2- and congenic TCR1-transduced CD45.1-CD45.2+ hematopoietic. (a)
Disease-free and overall survival of mice chimeric for WT (CD45.1+) and TCR1
(CD45.2+) T cells are plotted. (b) Ex-vivo proliferation of CD4+CD45.1+ (TCR1-) and
CD4+CD45.2+ (TCR1+) T cells from a representative 8 wk disease-free retrogenic
mouse was measured by CellTraceTM Violet dilution 72 hr after stimulation. (c)
Peripheral blood samples were collected at day 28 from mice chimeric for TCR1+ and
TCRWT T cells. The percent of CD4+TCR+CD45.2+ (TCR1+) T cells among total
CD4+TCR+ T cells in chimeric mice developing or not developing EAE is plotted. (d)
CD4+TCR+CD45.2+ (TCR1+) and CD4+TCR+CD45.1+ (TCRWT) T cells were flow
cytometrically sorted from 8 wk chimeric mice without current or historical signs of
EAE. The cells were stimulated as indicated and proliferation measured on day 3 by 3Hthymidine incorporation. (e) T cells from 8 wk disease-free chimeric mice were labeled
with CellTraceTM Violet and stimulated as indicated. At 72 hr, proliferation of
CD4+TCR+ CD45.2+ and CD45.1+ cells was determined as in figure 6h. The magnitude
of each division peak was divided by 2x, where x=division peak number, to estimate
numbers of parental cells whose progeny populated an individual peak. Based on this, the
percent of total parental cells that had divided was calculated and is plotted.
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Figure 3-14. Public TCRTCR impose MOG-reactive TCR repertoires.
(a) Proliferation of T cells from unprimed and disease-free retrogenic TCR4 mice was
measured by dye dilution 72 hr after stimulation as indicated. (b) The percent of initial
cells dividing in response to the indicated stimulus was calculated by dividing each
division peak by 2n, where n=division number, to estimate initial cell numbers forming
each peak. (c) Proliferative response of purified TCR4 T cells measured using 3Hthymidine incorporation. Circles indicate means of triplicates from individual mice. (d) T
cells from TCR7 retrogenic mice were isolated and stimulated as indicated. Proliferative
response was measured at 72 hr by 3H-thymidine incorporation. Circles indicate means of
triplicates from individual mice.
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Figure 3-15. Heightened public TCR autoreactivity.
(a) Kaplan-Meier analysis of alopecia-free and overall survival in TCR3 retrogenic
mice. (b) The dorsal surface of a representative TCR3 mouse demonstrates extensive
alopecia areata. (c) Premature catagen and inflammatory infiltrates in the follicular and
interfollicular epidermis, and inflammatory infiltrates associated with diffuse thickening
and hypercellularity of the squamous esophageal epithelium of a day 30 TCR3 mouse.
Immunohistochemistry for CD3+ cells demonstrates markedly increased T cell numbers
compared with a healthy control (CTRL) retrogenic mouse.
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TCR, or the 4 group 2 TCR that were identified in a single CNS but public in the
spleen. Mice expressing the 5 private group 3 TCR were also absent of clinical or
histologic disease (Figure 3-16).
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Figure 3-16. MOG35-55 response and disease-free survival of retrogenic mice.
MOG35-55 specific proliferation, disease-free survival, and overall survival is plotted for
group 1 (TCR1-6), group 2 (TCR 7-10), and group 3 (TCR 11-15) mice not
otherwise shown in other figures. (a) T cell proliferation to MOG35-55. CD4+ T cells were
purified from splenocytes from the indicated disease-free retrogenic mice and cultured
for 3 days in the presence of syngeneic irradiated splenic APCs in the absence of
additional stimulation or with 100 g ml-1 MOG35-55 or CD3/CD28. Cultures were
pulsed with 3H-thymidine at 72 hr and 3H incorporation measured. Circles indicate means
of triplicates from individual mice. No significant differences were identified between
unstimulated and MOG35-55 stimulated samples for the mice shown. (b) Kaplan Meier
analysis of disease free and overall survival of the indicated retrogenic mice is shown.
Disease-free and overall survival was 100% over the 120 day observation period for all
mice plotted except TCR10, of which 2 died without overt preceding illness or apparent
cause.

55

56

CHAPTER 4.

PRELIMINARY EXPERIMENTS
Introduction

Though TCR repertoire analysis has proved to be powerful tool in investigate the
relationship between Treg and Tconv cells, the disparity of the results conducted from
those experiments were affected by different mice model and sample size of the TCR
repertoire, and it is limited in that inferences are made by population shifts in the absence
of knowledge about antigen specificity. To better clarify the relationship between Treg
cells and Tconv cells, the best way is to study the specificity and responsiveness of Treg
and Tconv in the context of specific antigens. Our lab developed a retrogenic mouse
model of EAE in which the TCR chain locus was fixed by the enforced expression of a
TCR from a myelin oligodendrocyte glycoprotein (MOG)-specific T cell. TRBV13-2 is
expressed by almost half of MOG-specific T cells in MOG-EAE, and we focused on this
disease-associated repertoire101.
However, as we discussed in Chapter 3, public TCR distort repertoire response
characteristics and foster reactivity to specific autoantigens. We can benefit from
retrogenic mice models with enforced expression diseased associated public TCRchains
and investigate the Tconv and Treg TCR repertoires. To begin with, we will focus on the
TCR1 retrogenic mice for several reasons. First, it is the most commonly shared TCR1
in immunized mice and pre-immune mice. Second, it is presented on both Treg and
Tconv population, narrowing our TCR fine specificity analysis on the paring
TCRrepertoire. Third, TCRβ1 mice develop spontaneous EAE by imposing a high
frequency of MOG-reactive TCR repertoire, implying the close association between
TCRβ1 derived repertoire with MOG-EAE.
Results
We favor a model where the public TCRβ1‚ which pairs with degenerate TCRα
but still retains auto-reactivity, however, we cannot rule out the possibility that this public
TCRβ1 may impose a biased TCRα paring. Biased TCRα usage was observed on CNS
infiltrating cells in MOG-EAE mice, V9-J23 and V9-J31. However, there lacks
evidence to show whether this biased TCRα usage is TCRβ1 related126.
First we need to identify the TCR repertoire in TCRβ1 retrogenic mice. Mice
were sacrificed around day 30 post bone marrow transplant during their peak disease, and
CNS T cells were isolated. The number of specific Vα antibodies are very limited, only
Vα 2, Vα3.2, Vα5, Vα8.3 and Vα11 specific antibodies are commercialized. Flow
cytometric phenotyping of the isolated CNS T cells by using these Vα antibodies failed to
show any enriched TRAV usage compared with MOG-induced EAE mice (data not
shown). Since Vα nucleotide sequences are much more conservative than Vto
discriminate different Vα subtype, full length TCRα cDNA were generated by using 5’
RACE. CNS infiltrating T cells from TCRβ1 were sorted into Treg and Tconv population.
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cDNA were synthesized, amplified by using 21 Vα and Cα specific primers, and TA
subcloned into the pCR2.1 vector to create a cDNA library of TCRα chains. cDNA
containing plasmids will be randomly selected and sequenced. Vα, Jα, and CDR3α
regions will be interpreted by IMGT-V-QUEST (http://imgt.cines.fr).
Overall, 52 unique TCRα chains were identified from three mice (Table 3-6),
among which 29 were Tconv derived whereas 23 were Treg derived. The CDR3
sequences of those oligoclone types were heterogeneous and did not overlap between
mice, indicating that TCR1 is associated with diverse TCR. However, TRAV4 and
TRAV7 utilization were enriched in either Foxp3- Tconv cells (TRAV4: 17%, TRAV7:
35%) or Foxp3+ Treg cells (TRAV4: 48%, TRAV7: 26%), but we didn’t find any
evident enriched TRBJ usage (Figure 4-1).
Though we identified a number of TCRα from TCR1 CNS infiltrating cells, and
TCR1 was able to impose TCR MOG35-55 reactivity by paring with degenerate TCRα,
however, what antigen these T cells recognized in vivo was still unknown. They can be
either a MOG responder, a MOG non-responder but react to other cryptic self-antigen in
CNS138, or a just circulating bystander during the CNS inflammation. Therefore we fist
tested their MOG35-55 specificity in CD4 4G4 hybridoma T cell lines. Fourteen out of
fifty-two TCR reconstituted hybridoma cell lines demonstrated low to high MOG35-55
reactivity (Table 4-1). Next, we further tested their fine specificity of all MOG35-55
reactive TCR in peptide titration assay. In either Treg or Tconv population, TCR were
identified with high, moderate, and low sensitivity for MOG35-55 stimulation (Figure 4-2).
Nine out of eleven TCR with TRAV4 V region mediated moderate to high MOG35-55
response, no matter it was Treg or Tconv derived. In contrast, the other 2 TRAV4 TCR
were able to mediate very low MOG35-55 response, both of which were Treg derived. In
addition, 2 TRAV7 TCR mediated low to moderate MOG35-55 response, both of which
were Tconv derived. The only 1 TRACV13 TCR mediated high MOG35-55 response, and
it was from Tconv.
To find out whether MOG35-55 specificity in vitro was correlated with the
pathogenesis in vivo, retrogenic mice were made with enforced expression of particular
MOG35-55 specific TCRMice were followed for disease development for at least 80
days post bone marrow transfer. For most of the Tconv derived TCR (Figure 4-3a), mice
progressed spontaneous EAE symptoms with early T cell engraftment, only PUN308 was
observed for decreased incidents due to its poor engraftment. For those Treg derived TCR
(Figure 4-3b), PUN342 could induce severe spontaneous EAE, but Br11, Br17, Br25,
Br41, Br47 were observed with sporadic or no disease incidents which were associated
with low T cell engraftment. For PUN355 and PUN376, those TCRs showed low MOG3555 reactivity, no disease was observed even with good engraftments.
From these preliminary experiments, it seems impossible to simply correlate any
TRAV usage, T cell type, CDR3sequences or MOG35-55 specificity with pathogenesis
in vivo. PUN003 and PUN005 were Tconv derived with low MOG reactivity, but were
still able to induce spontaneous EAE otherwise high MOG reactive PUN308 was on the
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Figure 4-1. Pie charts of TRAV and TRAJ usage in TCRCNS infiltrating T
cells.
CNS infiltrating T cells were isolated from TCR retrogenic mice. cDNA was
synthesized, subcloned, and followed by Sanger sequencing (a) TRAV usage in Tconv or
Treg (b) TRAJ usage in Tconv or Treg.
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Table 4-1.

Fourteen reconstituted TCRwith MOG35-55 reactivity on hybridoma cells.

Constructs

Derived
TRAV
TRAJ
CDR3α
TRBV
TRBJ
CDR3β
cell type
Foxp3TRAV4D-3
TRAJ21
AAGGYNVLYF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN002
Foxp3
TRAV7-3
TRAJ27
AANTGKLTF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN003
Foxp3
TRAV7D-3
TRAJ37
AVGGNTGKLIF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN005
Foxp3
TRAV4D-4
TRAJ42
AASGGSNAKLTF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN307
Foxp3
TRAV4D-3
TRAJ49
AAVTGYQNFYF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN308
Foxp3
TRAV13D-1
TRAJ37
ALITGNTGKLIF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN323
+
Foxp3
TRAV4D-3
TRAJ42
AAGGSNAKLTF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN342
+
Foxp3
TRAV4D-4
TRAJ57
AAGQGGSAKLIF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN355
+
Foxp3
TRAV4D-3
TRAJ50
AARSSSSFSKLVF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
PUN376
+
Foxp3
TRAV4D-3
TRAJ33
AAPDSNYQLIW
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
BR11
+
Foxp3
TRAV4D-3
TRAJ57
AARQGGSAELIF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
BR17
+
Foxp3
TRAV4D-3
TRAJ40
AAPGNYKYVF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
BR25
+
Foxp3
TRAV4D-3
TRAJ39
AAGGDNAGAKLTF TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
BR41
+
Foxp3
TRAV4D-3
TRAJ50
AAIASSSFSKLVF
TRBV13-2
TRBJ2-1 ASGETGGNYAEQF
BR47
Identified TCR sequences from 5’ RACE were reconstituted with TCR1 and transduced into CD4 4G4 hybridoma cells. All the
hybridoma cell lines were treated with 100ug/ml MOG35-55 in the presence of syngeneic APCs. IL-2 production was measured by
ELISA at 24 hr. Fourteen out of total fifty-two unique TCR chains were further tested for their fine specificity.
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Figure 4-2. Titration assay for MOG35-55-specific TCR.
TCR reconstituted 4G4 CD4 hybridoma cells were tested for their fine specificity to
MOG35-55 stimulation in vitro. IL-2 production was analyzed by ELISA assay for
different cell lines bearing either Tconv (a) or Treg (b) T-cell derived TCR, stimulated
with varied doses of MOG35-55 peptide in the presence of syngeneic APCs. PUN342 line
is Treg derived TCR, used as an inner control for comparability. Data shown is
representative of 3 independent experiments with at least 2 independent transductions of
each TCR.
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Figure 4-3. MOG35-55 response and disease-free survival of TCR retrogenic
mice.
Kaplan Meier analysis of disease free of the indicated TCR retrogenic mice is shown.
TCRwas enforced expression with different TCRidentified from 5’RACE. Disease
development was followed in these retrogenic mice at least 80 days post bone marrow
transfer. Sick mice were sacrificed and analyzed before moribund. (a) Retrogenic mice
with Tconv derived TCRb) Retrogenic mice with Treg derived TCRData was
collected from at least 2 batches of retrogenic mice. Total mice number was indicated.
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opposite, indicating it was not a solely MOG35-55 specificity dependent pattern. The
situation seems more complicated for Treg derived TCR, high MOG reactive PUN342
could induce disease while low MOG reactive PUN355 and PUN376 could not, even
though PUN342 possess Tregs during the early disease (4.47±4.24% in CNS, 7.70±7.74%
in Spleen). On the other hand, several other Treg derived TCRs (Br11, Br17, Br25, Br41,
Br47) were observed with poor early T cell engraftment resulting in the sporadic or no
disease incidents. Interestingly, we noticed the CDR3 sequences of PUN342 and
PUN307 are almost identical except one extra “S” residue on the 3rd position of PUN342.
They were identified from distinct T cell population, however, both of them share similar
MOG35-55 specificity and pathogenesis. This “S” residue can be tolerated due to the
degeneracy of TCR specificity against MOG35-55-MHC ligand, but it may provide some
clues for T cell lineage commitment in the thymus.
Retrogenic mice developed spontaneous EAE around day 30 post bone marrow
transfer, for which early engraftment of those MOG35-55 specific T cells seems essential
for disease onset123. To investigate the relationship between early engraftment level and
disease, the data from retrogenic mice of Tconv derived TCRwere pooled together,
and disease onset day showed an inverse correlation against the CD4 T cell frequency in
blood lymphocytes on day 28, the higher level CD4 T cell frequency, the earlier the
disease (Figure 4-4). Treg derived TCR was not analyzed here because only PUN342
developed disease with detected level of engraftment. Therefore the data was limited for
Treg derived TCR.
Treg derived TCR would generate Tregs in retrogenic mice, whereas there was
not Treg cells in retrogenic mice expressing Tconv derived TCR123. Overlaid on this,
retrogenic mice with PUN342, which was identified from a Treg clonotype, still
developed severe spontaneous EAE with early T cell engraftment. Phenotypic analysis
were routinely performed on the retrogenic mice during their peak disease, a proportion
of Tregs was present in PUN342 retrogenic mice (Spleen: 7.7±7.7%; CNS: 4.7±4.2%)
and the absolute Treg cell number was Spleen: 4.1±5.3x104 CNS:1.3±1.2x104. However,
the disease seems not to be protected in the presence of this small fraction of Tregs.
There was also a low frequency of Tregs in the PUN308 retrogenic mice, but the
actual number was very limited. This might result from the background noise for flow
cytometry in retrogenic mice if the mice were poorly engrafted. There were very limited
Treg cells in the spleen of retrogenic mice expressing Tconv derived TCRs, which was
consistent with prior reports123,139. However, in some cases, a small number of Foxp3+
CD4+ T cells were observed in CNS. Those CNS Foxp3+ T cells might be expanded
nTreg or induced Treg responding to abundant antigenic stimulation (Figure 4-5).
Since the retrogenic mice develop spontaneous EAE with very early T cell
engraftment at ~4 wk, characterization of the mechanism undergoing during that time
point maybe suggestive. What antigens are those cells recognizing? Whether they are
antoantigens or foreign antigens? Why those activated T cells can migrate into CNS? The
commensal bacteria is associated with CNS disease140,141, so our first intuition was that
TCR cross-reactivity to the commensal microbial antigens stimulated the T cells. Then
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Figure 4-4. Disease onset is associated with early CD4 T cell engraftment.
Retrogenic mice were analyzed for CD4 T cell engraftment on day 28 post bone marrow
transfer. These engraftment data of Tconv derived TCR was pooled together and the
frequency of CD4 T cells gating in blood lymphocytes was plotted against disease onset
day, showing an inverse correlation pattern.
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Figure 4-5. Treg analysis of retrogenic T cells.
Flow cytometric analysis of surface-stained splenocytes from the indicated type of
retrogenic mouse is shown. Mice were sacrificed and analyzed during their peak disease
(disease score >3) (a) Frequency of Tregs either in spleen or CNS CD4 T lymphocyte
population. (b) Cellularity of Tregs either in spleen or CNS.
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we tried to test the responsiveness of four MOG35-55 specific TCR to MOG35-55 mimicry
peptides. They are PUN002 (Tconv, high MOG35-55 reactivity), PUN003 (Tconv,
moderate MOG35-55 reactivity), PUN003 (Tconv, low MOG35-55 reactivity) and PUN342
(Treg, high MOG35-55 reactivity). Though different TCR demonstrated variability, the
common patterns of reactivity when tested with alanine-substituted MOG35-55 peptides
were quite similar (Figure 4-6). Similar to prior studies characterizing the R41, F44,
R46, and V47 are critical MOG35-55 residues for specific TCR interacting142, stimulation
with common patterns of reactivity when tested with alanine-substituted MOG35-55
peptides alanine-substituted peptides such as F44A, R46A, V47A and V48A greatly blunt
the reactivity compared to original MOG35-55 peptide (Figure 4-6). These residues are
determinants for epitope specificity at least for these four TCR clonotypes, however, the
tolerance of TCR specificity to other alanine-substituted MOG35-55peptides suggests the
potential cross reactivity of the MOG35-55 reactive T cells responding to the MOG35-55
peptide mimicry. Since the experimental mice were conducted under specific germ free
condition, the mimicry peptides may be introduced from the commensal bacteria, and
lead to activation of the early engrafted MOG35-55 reactive T cells.
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Figure 4-6. Cross reactivity to MOG35-55 mimicry.
Four different 4G4 CD4 cell lines transduced with TCRwere tested for their
responsiveness to 100μg/ml MOG35-55 or MOG35-55 mimicry peptides by ELISA. The IL2 production was normalized to MOG35-55 group. Bars indicate from left to right IL-2
production by clonotype PUN002, PUN003, PUN005 and PUN342. Dashed line was an
indicator for MOG35-55. Mean ±SD is plotted.
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CHAPTER 5.

DISCUSSION

Public TCR in Skewing Repertoire Response and Autoimmune Susceptibility
In previous chapters, we talked about by linking saturation sequencing of diseaseassociated and unassociated repertoires during EAE with the transgenic expression and in
vivo functional analysis of 15 public and private TCR, we identify a selective and
prominent role of public TCR in the autoimmune response. Public TCR were
preferentially incorporated into the CNS-infiltrating repertoire. The frequency of unique
and total public TCR was markedly elevated when compared with TCR unengaged in
autoimmunity both from mice with EAE and from pre-immune mice. Three public but no
private TCR were able to confer unprimed T cells expressing endogenously rearranged
TCR with overt MOG-reactivity. Enforced expression of two of six CNS-shared TCR
provoked spontaneous autoimmunity in a mouse strain that does not otherwise develop
spontaneous autoreactivity. Our findings indicate that public TCR distort repertoire
response characteristics and foster reactivity to specific autoantigens.
Recombinatorial biases in preselection thymocytes serve as the primary source for
the generation of the broad public repertoire42,143-145. Predispositions in VDJ usage and
activity levels of TdT and nucleases modifying junctional sequences increase the
probability these sequences will form146. We implicate similar pre-selection biases in also
generating the public autoimmune repertoire, and identify substantial ongoing oligoclonal
production of public autoimmune-associated TCR within the thymus. As previously
documented by Dyson and colleagues with the larger public repertoire147, analyses of the
frequency of individual receptors in pre- and post-selection thymocytes and splenic T
cells further failed to indicate that, once formed, disease associated public TCR are
preferentially selected (data not shown).
Our results do not imply that public TCR possess unique structural properties that
distinguish them from private TCR. Indeed, despite comprising a small fraction of the
total repertoire, public sequences remain diverse. It would therefore seem unlikely that
their preferential recruitment into the autoimmune response when compared with private
sequences is due to a distinct biochemistry. Rather, because public TCR are pervasive
across a population, specificity distortions they introduce within the repertoire will be
introduced into all individuals bearing relevant MHC alleles. Thus, MOG35-55 may serve
as the dominant autoantigen in C57BL/6 EAE precisely because the public repertoire in
conjunction with the restricting MHC, IAb, augments repertoire reactivity toward this
autoantigen. Other neuroantigens preferentially engaged by private TCR would only be
capable of mediating autoimmunity in the small number of individuals that stochastically
possess adequate numbers and subsets of antigen-specific private T cells.
An alternative hypothesis for the preferential incorporation of public sequences in
the autoimmune repertoire is that these sequences do predispose TCR toward selfreactivity. Other repertoire studies, though more limited in scope and definition compared
with these, have also identified public sequences among autoreactive T cells123,125,148.
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That public TCR may more generically confer responsiveness to self-antigens is also
suggested by our finding that transgenic expression of the public, EAE-associated TCR3
chain led to the development of spontaneous alopecia areata and not EAE. Therefore, a
single TCR may promote reactivity to disease-associated autoantigens from different
tissues. In this regards, it is noteworthy that a previously isolated though distinct
TRBV13-2+ TCR from a MOG35-55-specific hybridoma, 1MOG244.2, was identified as
possessing two TCR chains. Transgenic expression of one TCR led to MOG35-55
reactive T cells. The second provoked spontaneous alopecia areata, suggesting a broader
association between CNS and skin reactivities149.
Public TCR use is not only identifiable in the context of autoimmunity, but has
also been found in the responses to several pathogens and other antigens42,127. One
possible explanation is that the recombinatorial activities involved in forming the public
repertoire also creates a public sequence space that more broadly supports TCR
associations with MHC-antigen complexes. The majority of the TCR interface with
antigen-MHC binds the MHC rather than antigenic peptide, and MHC-specific
associations are critical to stabilizing this interaction6,150. If the public repertoire
incorporates TCR better suited to support MHC engagement, these receptors may
preferentially enter immune responses. Such a model would suggest a co-evolution of the
public TCR repertoire with restricting MHC, presumably by modulating recombination
frequencies so as to optimize this component of the response. An element of enhanced
self-reactivity would be expected to accompany such increased TCR fitness. Indeed, TCR
mutations that enhance TCR-MHC association also promote self-reactivity and can
endow TCR with new autoreactivities151,152.
We found that 2 of the 6 group 1 (CNS-shared and public) TCR and altogether 3
shared TCR broadly imposed MOG specificity on TCR. MOG-responsiveness was
particularly prominent in mice expressing TCR1, where nearly 1/3 the number of CD4+
T cells from disease-free animals responding to CD3 proliferated to MOG35-55. Unlike
antibody-antigen interactions, which may rely on a single Ig chain, the TCR-MHC
interface extensively involves both the TCR and  surfaces. Implicitly, TCR1
dominates interactions defining specificity during MOG35-55-IAb recognition, and this is
accompanied by more generic interactions with TCR that are simply non-disruptive and
provide requisite supplemental association energy for effective T cell stimulation.
However, in the absence of structural definition, it cannot be excluded that TCR1 and
other public TCR chains bind autoantigens in non-conventional manners that minimize
reliance on the TCR.
The capacity to interrogate the repertoire continues to increase with improving
sequencing technologies26. Data sets are being collected in several disease models and
these may be linked to functional analyses of individual TCR, similar to those we
describe here, to identify the relevance of specific sequences. Indeed, the identification of
preferential TRBV and TRAV usage in several diseases may imply that public TCR or
TCR sequences bearing pre-defined V, J, and CDR3 sequences will strongly skew
response characteristics. If so, specific public sequences may prove useful for the
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longitudinal monitoring of immune responses during autoimmune diseases. Likewise if
public TCR ultimately prove not only to be over-represented and risk factors for the
autoimmune response as indicated here, but drivers of it as originally hypothesized by
Sercaz and colleagues153, it may be possible to broadly modulate the autoimmune
response by specifically guiding the selection or activity of T cells bearing public TCR
sequences.
Functional Characterization of TCR Repertoire in TCR1 Retrogenic Mice Model
Meanwhile, we performed preliminary experiments to characterize the
TCRrepertoire by using the TCR1 mice model, which generated narrowed repertoire
diversity with fixed TCR1 paring with endogenous TCRWe favor this mice model
for the following consideration. First, it is the most commonly shared TCR in
immunized mice and pre-immune mice. Second, it is presented on both Treg and Tconv
population, narrowing our TCR fine specificity analysis on the paring TCRrepertoire.
Third, TCRβ1 mice develop spontaneous EAE by imposing a high frequency of MOGreactive TCR repertoire, implying the close association between TCRβ1 derived
repertoire with MOG-EAE. Investigation on the composition of TCR chain repertoire
will potentially yield valuable information for the TCR structural features, specificity,
responsiveness, and lineage commitment of Treg and Tconv in the context of
autoimmune disease.
We were able to identify 52 unique clonotypes from CNS of 3 TCR1 retrogenic
mice. Though only a small number, these clonotypes were heterogeneous and did not
overlap between mice, indicating that TCR1 can associate with diverse TCR. TCR
were reconstituted and transduced into 4G4 CD4 hybridoma cells for MOG35-55 reactivity
test in vitro. Fourteen unique TCR showed low to high responses to MOG35-55 stimulation.
In order to investigate their potential pathogenesis against autoantigen in retrogenic mice,
we made retrogenic mice which express single TCR. All the Tconv derived TCR were
able to promote early spontaneous EAE, which seemed irrelevant to MOG specificity.
However, PUN342, a Treg derived TCR with high MOG35-55 reactivity, promoted early
spontaneous EAE even in the presence of Treg cells. While PUN355 and PUN376, Treg
derived TCR with low MOG35-55 reactivity, failed to promote any disease. This result
implicated that the presence of Treg cells were not able to protect the EAE induced by the
high MOG35-55 reactive T cells. Meanwhile, some retrogenic mice expressing PUN308
and several Treg derived TCRs (Br11, Br17, Br25, Br41, Br47) were noticed with poor
engraftment. A possible explanation would be that these TCR clonotypes under the
surveillance of central tolerance might hardly leak into the periphery. In C57BL/6 mice,
Delarasse et al. have shown that MOG transcripts are expressed in thymus154.
Nevertheless, the expression of MOG protein in human and mouse thymus has never
been reported so far. Therefore, the MOG specificity of clonotypes may not simply
correlated with the pathogenesis. Interestingly, we noticed that CDR3 sequences of two
clonotypes are similar except one additional “S” residue on the 3rd position of Treg
derived TCR. They are belonging to distinct T cell type, but sharing similar MOG
specificity and pathogenesis. This “S” residue can be tolerated due to the degeneracy of
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TCR specificity against MOG35-55-MHC ligand, but it seems critical for T cell lineage
commitment in the thymus. Due to the limited number and poor engraftment capability of
some TCR clonotypes, it is too early to come to any final conclusion that how fine
specificity of TCR is relevant to T cell commitment or pathogenesis.
Cross Reactivity, Gut and CNS
Since the retrogenic mice develop spontaneous EAE with very early T cell
engraftment, we are curious about what stimuli are recognized by those cells in vivo. We
examined the responsiveness of four MOG reactive TCR to MOG35-55 mimicry peptides.
Different TCR demonstrated variability, but common patterns of reactivity when tested
with alanine-substituted MOG35-55 peptides was evident. MOG35-55 mimicry peptides such
as F44A, R46A, V47A and V48A greatly blunted the reactivity compared to MOG35-55
stimulation, suggesting that these residues are critical to sustain the specificity of the
MOG35-55 peptide. Alternatively speaking, it may allow MOG35-55 -specific T cells to
cross-react to various MOG35-55 mimicry peptides with these four critical residues
unchanged. Here we propose these MOG35-55 mimicry peptide may come from the
antigens of commensal bacteria.
Due to the large number of clonotypically unique TCRs that can be generated by
V(D)J somatic recombination, it was initially believed that the immune system might be
capable of generating a TCR repertoire for virtually every antigenic peptide. However,
subsequent estimates of the size of the peptide pool recognized by TCRs revealed that
potentially immunogenic peptides in the environment of an individual greatly outnumber
the amount of T cells. Each T-cell is estimated to react with >106 different MHCassociated peptide epitopes155, for which the concept of TCR cross-reactivity has been
evoked as an essential mechanism to expand the effective size of the TCR
repertoire156,157. However, the degeneracy of TCR specificity will increase the pathogenic
potential T cells as it augments the likelihood of self-pMHC recognition. Indeed, several
studies have reported that TCR cross-reactivity and molecular mimicry is associated with
autoimmune disease, whereby the viral or bacterial peptides mimic autoantigens and
provoke the autoimmunity158,159. Moreover, structural studies provided substantial
evidence to reveal the recognition features of several autoreactive TCR-pMHC
complexes151,160-164. These features were summarized as altered TCR docking topologies,
paucity of hydrogen bonds between the TCR and self-peptide, peptide recognition by the
CDR3 loops alone, limited interactions between the TCR and MHC, suboptimal fit of the
self-peptide in the MHC binding groove and partial occupancy of the groove by the selfpeptide141. What these cross-reactive TCR actually recognize in vivo is unknown. Since
the mammalian gastrointestinal track can harbor a highly heterogeneous microbial
population comprising over 1x1013-1014 resident bacteria, commensal bacteria may
provide the most abundant foreign antigens that may mimic autoantigens in vivo.
Evidence has demonstrated the relationship between CNS demyelinating diseases and
commensal bacteria. For instance, in EAE mice model, alteration of the bacterial
populations of the gut has been demonstrated to alter the clinical outcome165. Oral
administration of antibiotics protected against EAE166.
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Based on this hypothesis, we proposed that microbial antigens may take
advantage of the similar molecular mimicries and activate the early engrafted retrogenic
T cells in the periphery. To test that in our pilot experiments, we were able to continually
treat our retrogenic mice with combined antibiotics. Those mice were either enforced
expressing fixed TCR chain (TCR1, TCR3) or enforced expressing single
TCR(PUN342). The autoimmune disease was completely prevented (Nguyen,
unpublished data). Retrogenic mice of control group were treated with syrup only, they
still developed spontaneous autoimmune disease and a substantial number of highly
activated CD4 T cells could be isolated from gut tissue and the mesenteric lymph nodes
(Nguyen, unpublished data).
In order to further clarify the mechanism, future experiments are necessary to
screen out the bacteria and the bacterial antigen if possible. Admittedly, the variation in
intestinal microbiota communities of the laboratory mice is dependent on the
environmental factors at each institutional facility. To circumvent this problem, germ-free
mice line is necessary to identify the association among the gut-microbiota antigen and
the CNS demyelinating diseases.
Retrogenic Mice Models versus Transgenic Mice Models
TCR transgenic mice are widely used and have had a large in current
immunological research. Several studies focusing on TCR repertoire analyses also
successfully utilized transgenic mice enforced the TCR chain with or without a TCR
chain minilocus97,100. This approach is much stable and natural since the T cell first
develop in the neonatal condition, but it is time consuming and costly, needs careful preexperiment design. Due to the time and cost inconvenience, this approach doesn’t fit a
comprehensive functional assessment of multiple public TCRβs.
To circumvent these problems, we utilized another commonly used mice model,
retrogenic mice, in which specific TCRs were retrovirally transduced into hematopoietic
stem cells136. This approach is substantially faster than making trangegnic mice, (6 weeks
versus 6 months), making a comprehensive functional assessment of multiple public
TCRβs possible. Compared with transgenic mice, there still exists some disadvantage,
such as less T lymphocytes, laborious effort to generate each mouse, unnatural phenotype
of peripheral T cells with an increased memory-like phenotype in a lymphopenic host
condition. In addition, we sublethally irradiated recipient mice to facilitate stem cell
engraftment, and how sublethal irradiation itself may affect the mice is hard to judge.
Furthermore, bone marrow transfer is required for making retrogenic mice model, the
more steps for manipulation, the more risk to expose to environmental antigens, meaning
studies about the spontaneous disease imposed by public TCR chains in germ free
condition is difficult.
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Admittedly, although we have not seen any deleterious consequences per se, these
effects can potentially influence experimental results and should be considered in
interpreting data from the system.
Summary
In summary, in this project, we were able to couple the high-throughput
sequencing of the TCR repertoire in EAE mice model, with functional studies
demonstrating the role of public TCR chains in disease susceptibility in retrogenic mice.
Analyses of >18 million TCR from Foxp3+ regulatory and Foxp3- conventional T cells
from different organs and time points, we identified a high prevalence of public TCR
within the autoimmune response. The public TCR are more likely to be formed in preselection thymocytes, which also reside in the pre immune repertoire and is preferentially
employed in autoimmune responses, suggesting the hidden “foes” may impose disease
risk once if the immune system is out of control. We also performed some pilot
experiments by treating the retrogenic mice with antibiotics, thus the autoimmune
diseases were totally protected, and suggesting the cross-reactivity towards the
commensal microbial antigens might activate the retrogenic CD4 T dells in periphery.
This experiment provides insights for the relationship between commensal bacteria and
the CNS demyelinating diseases. Though the underlying mechanism and the particular
antigens are not well understood, this study still provides a potential therapeutic insight.
Coupling high-throughput immunosequencing, specific public sequences may prove useful
for the longitudinal monitoring of immune responses during autoimmune diseases.
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APPENDIX A. SUPPLEMENTAL TABLES
Table A-1.

TCR1

Annealing oligo sequences for CDR3
Oligo
sense
antisense

TCR2

sense
antisense

TCR3

sense
antisense

TCR4

sense
antisense

TCR5

sense
antisense

TCR6

sense
antisense

TCR7

sense

5’ to 3’ nucleotide sequence
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGAGACTGGGGGAAACTATGCTGAGCAG
TTCTTCGGACCAGGGACACGACTCACCGTCCTAGAA
GATCTTCTAGGACGGTGAGTCGTGTCCCTGGTCCGAAGA
ACTGCTCAGCATAGTTTCCCCCAGTCTCACCGCTGGCAC
AGAAGTACACTGATGTCTGAGAGGGGGTAGCCAAC
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGACAGGTATGAACAGTACTTCGGTCCC
GGCACCAGGCTCACGGTTTTAGAA
GATCTTCTAAAACCGTGAGCCTGGTGCCGGGACCGAAG
TACTGTTCATACCTGTCACCGCTGGCACAGAAGTACACT
GATGTCTGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGCTATGAACAGTACTTCGGTCCCGGCACCA
GGCTCACGGTTTTAGAAGATCT
GATCTTCTAAAACCGTGAGCCTGGTGCCGGGACCGAAG
TACTGTTCATAGCCGCTGGCACAGAAGTACACTGATGTC
TGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGAAACAGCAAACTCCGACTACACCTTC
GGCTCAGGGACCAGGCTTTTGGTAATAGAAGATCT
GATCTTCTATTACCAAAAGCCTGGTCCCTGAGCCGAAGG
TGTAGTCGGAGTTTGCTGTTTCACCGCTGGCACAGAAGT
ACACTGATGTCTGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGATGCTGGGGGGTCCTATGAACAGTAC
TTCGGTCCCGGCACCAGGCTCACGGTTTTAGAAGATCT
GATCTTCTAAAACCGTGAGCCTGGTGCCGGGACCGAAG
TACTGTTCATAGGACCCCCCAGCATCACCGCTGGCACAG
AAGTACACTGATGTCTGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGATGGTGAACAGTACTTCGGTCCCGGC
ACCAGGCTCACGGTTTTAGAAGATCT
GATCTTCTAAAACCGTGAGCCTGGTGCCGGGACCGAAG
TACTGTTCACCATCACCGCTGGCACAGAAGTACACTGAT
GTCTGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGAGCAACAGGGGACTGAGCAGTTCTTC
GGACCAGGGACACGACTCACCGTCCTAGAAGATCT
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Table A-1.

(Continued).
Oligo
antisense

TCR8

sense

antisense
TCR9

sense

antisense
TCR10

sense
antisense

TCR11

sense
antisense

TCR12

sense
antisense

TCR13

sense
antisense

5’ to 3’ nucleotide sequence
GATCTTCTAGGACGGTGAGTCGTGTCCCTGGTCCGAAGA
ACTGCTCAGTCCCCTGTTGCTCACCGCTGGCACAGAAGT
ACACTGATGTCTGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGATGGACTGGGGGGCTCCTATGAGCAG
TACTTCGGTCCCGGCACCAGGCTCACGGTTTTAGAAGAT
CT
GATCTTCTAAAACCGTGAGCCTGGTGCCGGGACCGAAG
TACTGCTCATAGGAGCCCCCCAGTCCATCACCGCTGGCA
CAGAAGTACACTGATGTCTGAGAGGGGGTAGCCAACTC
GAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGATGTCCGGGGCTATAATTCGCCCCTCT
ACTTTGCGGCAGGCACCCGGCTCACTGTGACAGAAGAT
CT
GATCTTCTGTCACAGTGAGCCGGGTGCCTGCCGCAAAGT
AGAGGGGCGAATTATAGCCCCGGACATCACCGCTGGCA
CAGAAGTACACTGATGTCTGAGAGGGGGTAGCCAACTC
GAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGATGGAACATCAAACTCCGACTACACC
TTTGGGCCAGGCACTCGGCTCCTCGTGTTAGAAGATCT
GATCTTCTAACACGAGGAGCCGAGTGCCTGGCCCAAAG
GTGTAGTCGGAGTTTGATGTTCCATCACCGCTGGCACAG
AAGTACACTGATGTCTGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGGATAGGGGACACCCAGTACTTTGGGCCA
GGCACTCGGCTCCTCGTGTTAGAAGATCT
GATCTTCTAACACGAGGAGCCGAGTGCCTGGCCCAAAG
TACTGGGTGTCCCCTATCCCGCTGGCACAGAAGTACACT
GATGTCTGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGTGACGCCGGGACAGGGTATGAACAGTAC
TTCGGTCCCGGCACCAGGCTCACGGTTTTAGAAGATCT
GATCTTCTAAAACCGTGAGCCTGGTGCCGGGACCGAAG
TACTGTTCATACCCTGTCCCGGCGTCACCGCTGGCACAG
AAGTACACTGATGTCTGAGAGGGGGTAGCCAACTCGAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
GTGCCAGCGGGGACTGGGGGGGCGAAGACACCTTGTAC
TTTGGTGCGGGCACCCGACTATCGGTGCTAGAAGATCT
GATCTTCTAGCACCGATAGTCGGGTGCCCGCACCAAAGT
ACAAGGTGTCTTCGCCCCCCCAGTCCCCGCTGGCACAGA
AGTACACTGATGTCTGAGAGGGGGTAGCCAACTCGAG
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Table A-1.

(Continued).
Oligo
sense

5’ to 3’ nucleotide sequence
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
TCR14
GTGCCAGCGGTGATGAGACTGGGGGGGCCTATGAACAG
TACTTCGGTCCCGGCACCAGGCTCACGGTTTTAGAAGAT
CT
antiGATCTTCTAAAACCGTGAGCCTGGTGCCGGGACCGAAG
sense
TACTGTTCATAGGCCCCCCCAGTCTCATCACCGCTGGCA
CAGAAGTACACTGATGTCTGAGAGGGGGTAGCCAACTC
GAG
TCGAGTTGGCTACCCCCTCTCAGACATCAGTGTACTTCT
TCR15 sense
GTGCCAGCGGTGGGGGACTGGGGGGTACTAGTGCAGAA
ACGCTGTATTTTGGCTCAGGAACCAGACTGACTGTTCTC
GAAGATCT
antiGATCTTCGAGAACAGTCAGTCTGGTTCCTGAGCCAAAAT
sense
ACAGCGTTTCTGCACTAGTACCCCCCAGTCCCCCACCGC
TGGCACAGAAGTACACTGATGTCTGAGAGGGGGTAGCC
AACTCGAG
Nucleotide sequences of sense and anti-sense oligos for 15 CDR3are listed.
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APPENDIX B. SUPPLEMENTAL FIGURES

Figure B-1. Diagram of two main plasmids.
(a). MSCV-TCR1-GFP. (b). MSCV-244.2-TCR1-GFP
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Figure B-2. Gating strategy for surface staining on TCR1 retrogenic mice.
Cells were isolated from spleen and CNS and stained with specific antibodies. Flow
cytometric analysis was performed on an LSRFortessa and analyzed by using FlowJo
software. The cells were first gated on lymphocytes, gated out autofluorescent cells,
doublets, and gated on CD4+TCR+ or CD8+TCR+ lymphocytes. CD4+TCR+ lymphocytes
were further analyzed based on their CD44 (memory/effector), CD45Rb (naïve), and
CD69 (activation) markers.
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Figure B-3. Gating strategy for Foxp3 intracellular staining on TCR1 retrogenic
mice.
Cells were isolated from spleen and CNS and stained with specific antibodies. Cells were
first stained with surface markers, fixed, permeabilized and stained for intracellular
Foxp3 with the Foxp3 Staining Buffer Set. The cells were first gated on lymphocytes,
gated out autofluorescent cells, doublets, and gated on CD4+TCR+ lymphocytes.
CD4+TCR+ lymphocytes were further analyzed based on their Foxp3 marker.
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